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Background: Aneurismal subarachnoid hemorrhage is the most devastating type 
of stroke, with two thirds of the affected individuals either die or remain with 
moderate to severe disability. The majority of patients die during the first few 
days after subarachnoid hemorrhage (SAH) (Macpherson, Lewsey et al. 2011). 
This mortality is most likely attributed to a severe, cerebral perfusion pressure- 
independent reduction of cerebral blood flow (CBF). The mechanisms of this 
CBF decrease are largely unknown and may be related to disturbances at the - 
level of the cerebral microcircuiation. This project is an attempt to study the 
pathophysiological mechanisms by which subarachnoid hemorrhage leads to 
cerebral perfusion pressure- independent cerebral ischemia. We examined the 
most widely accepted theory that oxyhemoglobin induced nitric oxide depletion 
plays a key role in the etiology of cerebral ischemia and brain injury after sub­
arachnoid hemorrhage. In order to achieve this, we investigated any role intra- 
vascularfree hemoglobin might play in causing nitrogen oxide depletion by 
measuring plasma hemoglobin levels after experimental subarachnoid hemor­
rhage and comparing it with normal animals. We then studied cerebral microcir­
cuiation at 1-3 hours after experimental subarachnoid hemorrhage to check for 
any ischemic changes at this stage after experimental and, also, to test the cor­
relation between perivascular blood, which served as an index for perivascular 
hemoglobin, and these ischemic changes.
S u m m a r y
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Methods: Subarachnoid hemorrhage was induced in C57/BL6 mice using Circle 
of Willis endovascular perforation technique (Feiler, Friedrich et al. 2010). 
Intravital fluorescence microscopy was used to study cerebral microcirculation 1- 
3 hours after experimental subarachnoid hemorrhage. Plasma hemoglobin-was 
measured using the spectrophotometric scanning method of Blakney and 
Dinwoodie.
Results: Animals had normal physiological parameters throughout the experi­
mental period. Post-hemorrhagic intracranial pressure (ICP) rose to 91 +/- 29 
mmHg, indicating a comparable severity of SAH in all animals. 56% of observed 
cerebral vessels were affected by microvasospasm and microthrombosis. These 
changes were mainly seen in capillaries and small arterioles. 39% of all vaso­
spasms were detected in vessels with 10-20 pm caliber, 28% of vasospasms 
occurred in vessels with 20-30 pm caliber and 10% in blood vessels with 30-40 
pm in diameter. 59% of microthrombi were seen blood vessels <10 pm in diame­
ter and 37% of them occur in vessels with 10-20 pm calibers. 93% of all 
microvasospasm are associated with blood in the perivascular space compared 
to only 7% of vasospasm occurring in the absence of perivascular blood. 79% of 
microthrombi were observed in vessels coated with perivascular blood, com­
pared to 21% of microthrombi detected in the absence of perivascular blood. 
Plasma hemoglobin levels at 3 & 24 hours after experimental subarachnoid 
hemorrhage were similar to levels of plasma hemoglobin in control animals. 72 
hours after SAH, the levels are higher in SAH animals but the difference is not 
statistically significant.
Conclusions: As early as 1 hour after subarachnoid hemorrhage there are wide­
spread microvasospasms and microthrombosis affecting cerebral microcircula­
tion. These changes are severe enough and extensive enough to cause early 
post hemorrhagic cerebral ischemia and to serve as an explanation for early 
mortality following SAH. Extra- rather than intra-vascular hemoglobin is most 
likely responsible for cerebral microvasospasm and microthrombosis after ex­
perimental subarachnoid hemorrhage.
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C h a p t e r  1
IN TR O D U C TIO N
When persons in good health are suddenly seized with 
pains in the head, and straightway are laid down speech­
less, and breathe with stertor, they die in seven days.
Hippocrates 460-370 B C , A p h o r is m s  o n  A p o p le x y
1.1. Aneurismal subarachnoid hemorrhage
Aneurismal subarachnoid hemorrhage (SAH) is a type of hemorrhagic stroke
caused by the rupture of an intracranial aneurysm. It accounts for 75-85% of all
cases of spontaneous (non-traumatic) subarachnoid hemorrhage(van Gijn J Fau
- Kerr, Kerr Rs Fau - Rinkel et al.). Its estimated annual raté in most western
populations is 6-10 per 1 0 0 ,0 0 0  (L in n , Rinkel et al. 1996; Forget, Benitez et al.
2001 ; Seibert, Tummala et al. 2011). Aneurismal subarachnoid hemorrhage also
represents 15% of all intracranial hemorrhages and about 5% of all strokes
(Pluta 2005; Macpherson, Lewsey et al. 2011). It has unique pathophysiological
characteristics that differentiate it from other forms of intracranial hemorrhage
(epidural, subdural, intraventricular and intracerebral hemorrhages). First, the
source of the bleeding in aneurismal subarachnoid hemorrhage is usually one of
the major intracranial arteries, which will, therefore, result in a high pressure/
high volume hemorrhage that can cause serious brain damage. Second, the
clots that result from subarachnoid hemorrhage are poorly localized and spread
throughout the subarachnoid space and remain there for days covering blood
vessels (Zhang Zd Fau - Yamini, Yamini B Fau - Komuro et al. ; Pluta 2005).
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The presence of blood in direct contact with cerebral blood vessels will precipi­
tate alterations in the physiological forces that regulate the vascular tone leading 
to widespread vasospasm, which will result in reduced cerebral blood flow and 
cerebral ischemia (Zhang Zd Fau - Yamini, Yamini B Fau - Komuro et al.).
1.2. Cerebral aneurysms
Cerebral aneurysms are detected in 2-6% of the population (Wardlaw and White 
2000; White and Wardlaw 2003; Pluta 2005; Seibert, Tummala etal. 2011). The 
percentage of ruptured: unruptured aneurysm is 1:1, i.e. 50% of these aneu­
rysms rupture (Greenberg 2006). The most frequent and most serious presenta­
tion of ruptured intracranial aneurysms is major subarachnoid hemorrhage 
(Seibert, Tummala et al. 2011). Aneurismal subarachnoid hemorrhage is often 
accompanied by other pathologies such as intracerebral hemorrhage (19-40%) 
(Tokuda, Inagawa etal. 1995; Kopera, Majchrzak et al. 1999), intraventricular 
hemorrhage (13-28%) (Greenberg 2006) and acute hydrocephalus (20%) 
(Hasan, Lindsay etal. 1991; Suarez-Rivera 1998). Coexistence of any of these 
pathologies along with aneurismal subarachnoid hemorrhage adversely affects 
the prognosis and adds to the already high mortality and morbidity in these pa­
tients (Hauerberg J Fau - Eskesen, Eskesen V Fau - Rosenorn et al.; Nakaga- 
wa T Fau - Suga, Suga S Fau - Mayanagi et al. ; Mohr, Ferguson et al. 1983; 
Hasan, Lindsay etal. 1991; Suarez-Rivera 1998; Mayfrank, Hutteretal. 2001; 
Rosengart, Schultheiss et al. 2007).
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The exact pathophysiological mechanisms responsible for the formation of cere­
bral aneurysms are not fully understood. Cerebral arteries have certain charac­
teristics that make them susceptible to the development of aneurysms. In con­
trast to extracranial blood vessels, cerebral arteries have less elastic tissue in 
the tunica media and adventitia, a thinner adventitial layer and lesser muscle 
mass in the tunica media (Wilkinson 1972; Greenberg 2006). In addition, cere­
bral blood vessels lie within the subarachnoid space, and that is why they have 
very little supporting connective tissue (Greenberg 2006). Most aneurysms tend 
to develop at the bifurcations of cerebral arteries, where there is irregularity in 
the collagen matrix in the arterial wall and there is maximum hemodynamic 
stress generated by alterations of the radii of blood vessels at these bifurcations 
(Foutrakis, Yonas et al. 1999; Turner, Tebbs et al. 2001). This predilection of 
aneurysms for the bifurcation sites stresses the importance of hemodynamic 
stresses (Roach, Scott et al. 1972; Foutrakis, Yonas et al. 1999; Turner, Tebbs 
et al. 2001; Nixon, Gunel etal. 2010; Cebral, Mutetal. 2011; Cebral, Mut etal. 
2011) and structural alteration of the arterial wall (Scanarini, Mingrino et al.
1978; Kim, Cervos-Navarro etal. 1993; Kulcsar, Ugron et al. 2011) in the devel­
opment of cerebral aneurysms. Congenital as well as acquired factors combine 
to mediate the formation, growth and rupture of cerebral aneurysms. It’s be­
lieved that certain individuals have genetic predisposition to the development of 
cerebral aneurysms due to inherited malformations of the arterial walls, such as 
defects in reticular fibers in the medial layer (Hegedus ; Ostergaard, Reske- 
Nielsen et al. 1989; Chyatte, Reilly et al. 1990; Ostergaard 1991) or disruption of
the internal elastic lamina (Yong-Zhong and van Alphen 1990; Kim, Cervos- 
Navarro et al. 1993). Acquired factors such as atherosclerosis (de la Monte, 
Moore et al. 1985), hypertension (Franks 1978; de la Monte, Moore et al. 
1985)and smoking (Weir Bk Fau - Kongable, Kongable Gl Fau - Kassell et al.; 
Rinkel, Djibuti et al. 1998; Juvela, Porras et al. 2008) also play an important role 
in the etiology of cerebral aneurysms, probably in the setting of an existing con­
genital predisposition (Pluta 2005; Greenberg 2006). The most common type of 
intracranial aneurysms is saccular aneurysms or berry aneurysms. These are 
usually located on major intracranial arteries at branching or bifurcating points 
along these arteries (Ferguson 1972; Foutrakis, Yonas et al. 1999; Kulcsar, 
Ugron et al. 2011). About 85-90% of berry aneurysms occur in the carotid sys­
tem in one of the arteries forming the Circle of Willis at the base of the brain (in­
ternal carotid artery, middle cerebral artery, anterior cerebral artery, anterior 
communicating and posterior communicating) (Okuyama T Fau - Sasamori, 
Sasamori Y Fau - Takahashi et al.; Greenberg 2006), and 5-15% occur in the 
vertebrobasilar system, predominantly in one of the following three arteries: ver­
tebral artery, basilar artery and the posterior inferior cerebellar artery 
(Greenberg 2006).
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Aneurismal subarachnoid hemorrhage is regarded as the most fatal type of 
stroke. About 16% of individuals who suffer aneurismal subarachnoid hemor­
rhage die before reaching medical care (Pobereskin 2001; Macpherson, Lewsey 
et al. 2011). Despite advances in treatment, that led to decline in mortality rates 
over the past three decades (Hop, Rinkel et al. 1997; Nieuwkamp, Setz et al. 
2009; Macpherson, Lewsey et al. 2011), 28% of patients still die within 30 days 
of the onset of subarachnoid hemorrhage (Nieuwkamp, Setz et al. 2009). Among 
those who survive 30% remain with moderate to severe disability(Hop, Rinkel et 
al. 1997). Overall, Two thirds of patients with aneurismal subarachnoid hemor­
rhage will either die or end with moderate to severe disability (Seibert, Tummala 
et al. 2011). Around 21% of all mortalities occur during the first 24 hours 
(Pobereskin 2001), suggesting that the acute brain injury from the initial hemor­
rhage is responsible for the greatest proportion of the mortalities. Another im­
portant factor which is responsible for this high morbidity and mortality is re­
bleeding, which accounts for 15-20% of all mortalities. Re-bleeding and acute 
hydrocephalus are the only two major mortality factors that can be prevented or 
treated successfully. Delayed cerebral vasospasm, or angiographic vasospasm, 
which occurs 72 hours after thé hemorrhage and affect large cerebral arteries, is 
considered to be the cause of death in 7% of patients and to cause neurological 
deficit in another 7%(Greenberg 2006). Hence, the phenomenon of delayed cer­
ebral vasospasm has been the focus of extensive experimental and clinical re­
search, looking for effective therapies to tackle vasospasm, and reduce the inci­
1.3. Mortality & morbidity from aneurismal subarachnoid hemorrhage
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dence of cerebral ischemia and delayed ischemic neurological deficit. Over the 
years, there has been a reduction in the incidence of delayed cerebral vaso­
spasm, by itself, but that did not reduce the incidence of cerebral ischemia or 
improve the long term outcome (Macdonald, Pluta et at. 2007; Beck and Raabe 
2011). In fact, delayed ischemic injury and poor outcome are not always associ­
ated with delayed cerebral vasospasm (Vergouwen, Vermeulen et al. 2008).
2 1 %  o f S A H  survivors, who do not have delayed vasospasm, develop delayed 
ischemic injury (Alaraj, Charbel et al. 2009; Sehba, Pluta et al. 2011), and only 
20-30% of those, who do develop delayed vasospasm, actually, suffer from de­
layed ischemic injury (Alaraj, Charbel et al. 2009; Sehba, Pluta et al. 2011). In 
addition, therapies that successfully treat angiographic vasospasm failed to im­
prove the clinical outcome in patients with aneurismal subarachnoid hemor­
rhage. The latest example is the findings from the three phases of the endotheli­
al receptor antagonist, clazosentan, trial in patients with aneurismal subarach­
noid hemorrhage, which showed that although the drug reduced the incidence of 
vasospasm, it did not improve the clinical outcome (Vajkoczy, Meyer et al. 2005; 
Macdonald, Kassell et al. 2008; Macdonald, Higashida et al. 2011). Similar re­
sults were obtained with transluminal balloon angioplasty, which was effective 
against angiographic cerebral vasospasm, but failed to improve the long term 
clinical outcome (Coenen, Hansen et al. 1998; Polin, Coenen et al. 2000; Murai, 
Kominami et al. 2005). O n  the other hand, there are other therapies which im­
prove the clinical outcome without showing any effect on angiographic vaso­
spasm. The use of calcium channel antagonist nimodipine, for example, has
beneficial effects on the outcome of patients with aneurismal subarachnoid 
hemorrhage without preventing angiographic vasospasm (Philippon, Grob et al. 
1986; Jan, Buchheit et al. 1988; Petruk, West et al. 1988; Feigin, Rinkel et al.
1998). More importantly, 75% of all mortalities occur within 72 hours after the 
subarachnoid hemorrhage (Pobereskin 2001). Therefore, it’s evident from the 
outcome statistics that the mortality rates are highest during the first 2 4 - 7 2  
hours after the hemorrhage. This indicates that the pathophysiological events 
that take place within this early period after the hemorrhage determine the prog­
nosis of these patients. Because of the observations that the mortality rates are 
highest during the first 72 hours, and the persistence of ischemic brain injury 
and poor outcome irrespective of delayed cerebral vasospasm, the focus of ex­
perimental and clinical research has shifted towards studying the mechanisms 
that lead to the early brain injury that occurs during the first 72 hours following 
subarachnoid hemorrhage.
1.4. Early brain injury after subarachnoid hemorrhage
The mechanisms of early brain injury after aneurismal subarachnoid hemor­
rhage are not fully understood. The two main events that are produced by sub­
arachnoid hemorrhage and can potentially cause early brain damage are the ini­
tial burst of blood at the time of aneurysm rupture and the presence of blood 
within the subarachnoid space afterwards. Each of these two events evokes a 
sequence of pathophysiological responses that can result in early brain injury. 
The release of blood from the ruptured aneurysm triggers a series of changes in
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the hemodynamics of the cerebral circulation. These changes have been exten­
sively studied in experimental and clinical studies, and the results of these stud­
ies have led to important conclusions in the understanding of the mechanisms of 
early brain injury after subarachnoid hemorrhage. A summary of the cerebral 
hemodynamic changes caused by initial bleeding can be drawn from these stud­
ies. The sudden burst of blood from the ruptured aneurism causes an immediate 
and sharp rise in intracranial pressure (ICP) within seconds (Heuer Gg Fau - 
Smith, Smith Mj Fau - Elliott et al.; Westermaier T Fau - Jauss, Jauss A Fau - 
Eriskat et al.; Bederson, Germano et al. 1995; Torok, Klopotowski et al. 2009; 
Feiler, Friedrich et al. 2010; Schubert, Seiz et al. 2011). After reaching the peak, 
ICP gradually decreases within minutes, reaching a plateau at figures that are 
above its baseline values (Bederson, Germano et al. 1995; Feiler, Friedrich et 
al. 2010). Concomitant to the initial surge in ICP after SAH, cerebral perfusion 
pressure (CPP) falls sharply (Bederson, Germano et al. 1995; Prunell,
Mathiesen et al. 2003; Feiler, Friedrich et al. 2010), reaching its lowest value 
within 60 seconds after subarachnoid hemorrhage (Bederson, Germano et al.
1995). Cerebral blood flow (CBF) follows CPP during this period and drops 
sharply (Westermaier T Fau - Jauss, Jauss A Fau - Eriskat et al.; Bederson, 
Germano et al. 1995). After reaching its lowest value (within a minute of the on­
set of SAH), CPP starts to recover and gradually increases towards the base­
line, ultimately reaching values that are above cerebral autoregulation threshold. 
However, CBF continues to decrease and reaches its lowest value at a time 
when CPP is increasing towards baseline (Westermaier T Fau - Jauss, Jauss A
Fau - Eriskat et al.; Bederson, Germano et al. 1995). Ultimately, by 60 minutes 
after SAH, CBF remains 50-80% below its baseline values despite CPP return­
ing to values that are normally sufficient to maintain normal CBF (around 
50mmHg) (Bederson, Germano et al. 1995; Prunell, Mathiesen et al. 2003; 
Feiler, Friedrich et al. 2010). These findings are further augmented by similar 
observations in clinical studies. Schubert et al. observed a persistent and severe 
reduction of cerebral blood flow in patients during the first 12 hours after SAH 
despite the presence of normal ICP and CPP (Schubert, Seiz et al. 2009). Thus, 
it's evident that factors other than CPP are important contributors to the acutely 
decreased cortical blood flow after SAH. Primary reduction of cerebral metabolic 
activity, and acute SAH-induced vasoconstriction are two potential mechanisms 
proposed to be responsible for the CPP independent reduction of cortical blood 
flow following SAH (Bederson, Germano et al. 1995; Nieuwkamp, Setz et al. 
2009; Westermaier, Jauss et al. 2009). Carpenter et al. reported a reduced re­
gional cerebral oxygen metabolism on positron emission tomography ( PET) 
scans of patients in the early stages after aneurismal subarachnoid hemorrhage 
without evidence of angiographic vasospasm (Carpenter, Grubb et al. 1991). 
However, experimental studies examining cerebral blood flow and cerebral met­
abolic activity simultaneously have found that the decrease in cerebral blood 
flow precedes the decrease of cerebral metabolic activity, indicating that reduc­
tion in cerebral metabolic activity is not responsible for reduced CBF (Bederson, 
Germano et al. 1995). Hence, it’s concluded that acute vasoconstriction, most 
probably at the microcirculatory level, is the most likely mechanism leading to
the CPP independent reduction in CBF which is seen in the early stages after 
subarachnoid hemorrhage (Schubert, Seiz et al. 2009). The significance of mi- 
crocirculatory vasospasm as a cause of acute hypoperfusion after SAH is high­
lighted by the dissociation between the presence of reduced cerebral perfusion, 
and angiographic evidence of vasospasm, a phenomenon that has been de­
scribed in many clinical studies (Jakobsen M Fau - Overgaard, Overgaard J Fau
- Marcussen et al. ; Grubb, Raichle et al. 1977; Kelly, Gotten et al. 1977). From 
these studies, collectively, we can see that there is enough clinical and experi­
mental evidence to suggest acute microcirculatory vasospasm contributes di­
rectly to ischemic brain injury and poor outcome following subarachnoid hemor­
rhage (Bederson Jb Fau - Levy, Levy Al Fau - Ding et al. ; Sehba, Ding et al.
1999). Although the ICP does rise to ischemic levels as the blood bursts from 
the ruptured aneurysm, this is unlikely to contribute significantly to early brain 
damage because these ischemic ICP levels last only for few minutes.
1.5. Mechanisms of acute microcirculatory vasoconstriction
The exact mechanisms mediating acute vasoconstriction after subarachnoid 
hemorrhage are not entirely clear. The subarachnoid hemorrhage results in thick 
subarachnoid blood clots coating the adventitial surfaces of cerebral arteries 
(Findlay, Macdonald et al. 1991). It is well known that the distribution and severi­
ty of post hemorrhagic vasospasm correlates well with the volume and distribu­
tion of the subarachnoid blood clots on the computerized tomography (CT) 
scans of patients with aneurismal subarachnoid hemorrhage (Fisher, Kistler et
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al. 1980; Kistler, Crowell et al. 1983; Findlay, Macdonald et al. 1991). The exact 
element of blood that causes vasospasm has been the subject of intense re­
search. The whole blood by itself is well known to have a definite spasmodic ac­
tion on cerebral arteries (Echlin 1965; Zervas, Kuwayama et al. 1973; White, 
Hagen et al. 1975). However, the vasoconstrictor action of the subarachnoid 
hematoma is attributed to the red blood cells (RBCs) component of the hemato­
ma (Duff, Louie et al. 1988; Mayberg, Okada et al. 1990; Nozaki, Okamoto et al. 
1990; Peterson, Roussos etal. 1990; Yamamoto, Cloweretal. 1991). After sub­
arachnoid hemorrhage, the RBCs remain in the subarachnoid space for days, 
undergoing a process of slow hemolysis (Mayberg, Okada et al. 1990; Yamamo­
to, Clower et al. 1991). This process of hemolysis is essential for the for the 
spasmogenic action of the RBCs, because intact RBCs does not constrict cere­
bral arteries (Macdonald and Weir 1991). The result of RBCs hemolysis is the 
release of hemoglobin and its metabolites from the RBCs into the perivascular 
space. Of all the hemoglobin metabolites, oxyhemoglobin has been identified as 
the principal spasmogen responsible for cerebral vasospasm after subarachnoid 
hemorrhage (Asano ; Kajikawa H Fau - Ohta, Ohta T Fau - Yoshikawa et al. ; 
Macdonald, Weir etal. 1991; Pluta, Oldfield etal. 1997; Pluta, Afshar et al.
1998). Oxyhemoglobin has several mechanisms of action that can explain its 
role in the etiology of post hemorrhagic cerebral vasospasm. Particularly im­
portant action of oxyhemoglobin, which attracted huge interest, is its ability to 
cause depletion of nitric oxide (NO) from the vascular wad. Oxyhemoglobin is a 
powerful scavenger of NO due to the very high affinity between NO and the
heme moiety of the hemoglobin molecule, (Goretski and Hollocher 1988; Ignarro 
1990). It is hypothesized that the NO scavenging effect by oxyhemoglobin is 
compounded by decreased production of NO, which is caused by 
oxyhemoglobin induced inhibition of both endothelial (Jung Cs Fau - luliano, 
luliano Ba Fau - Harvey-White et al.) and neuronal (Pluta, Thompson et al.
1996) nitric oxide synthase (NOS), and these two actions will, ultimately, result 
in depletion of NO from the vascular wall. It’s known that NO is an important 
autoregulatory molecule in the cerebral circulation with many physiological roles 
including activation of soluble guanylate cyclases, which increase production of 
cyclic guanosine monophosphate leading to the relaxation of the vascular 
smooth muscles and vasodilatation (Guix, Uribesalgo et al. 2005). The depletion 
of nitric oxide from the vessel wall will, therefore, remove its vasodilatory effects, 
leading to vasospasm under the influence of unopposed vasoconstrictor mecha­
nisms such as endothelin-1.
The effects of acute post hemorrhagic microcirculatory vasospasm on cerebral 
perfusion are compounded by the presence of wide spread microthrombosis 
across cerebral microcirculation in the early stages after subarachnoid hemor­
rhage. These wide spread microthrombi have been demonstrated in experi­
mental studies within minutes of subarachnoid hemorrhage (Sehba, Mostafa et 
al. 2005). They have also been demonstrated on transcranial Doppler ultra­
sound studies of patients with aneurismal subarachnoid hemorrhage (Romano, 
Forteza et al. 2002). Similar to vasospasm, the amount and distribution of 
microthrombi is shown to strongly correlate with the volume and distribution of
the subarachnoid blood (Stein, Browne et al. 2006) Moreover, microvasospasm 
and microthrombi predominately occur in the same vessels in close proximity to 
one another, with microthrombi typically occupying the proximal ends of 
microvasospasms (Friedrich, Flores etal. 2010; Friedrich, Muller etal. 2011). 
This suggests a common factor is, perhaps, responsible for the etiology of both. 
Depletion of NO from the vascular wall, which is regarded as the most likely 
mechanism responsible for post-hemorrhagic vasospasm (Pluta, Dejam et al. 
2005), causes platelet aggregation and thrombus formation by removing the in­
hibitory effects of NO on platelets aggregation (Friedrich, Flores et al. 2010). 
Thus, it’s generally believed that, NO depletion, induced by oxyhemoglobin re­
leased from the hemolytic break down of the RBCs within the subarachnoid 
blood clot, mediates the formation of microcirculatory vasospasm and 
microthrombosis, leading to microcirculatory dysfunction and CPP independent 
acute cerebral hypoperfusion, which will ultimately result in ischemic brain injury 
in patients with aneurismal subarachnoid hemorrhage.
1.6. The aim of the current project
One of the main pillars of the hypothesis of hemoglobin induced NO depletion is 
the cause of post- hemorrhagic cerebral vasospasm and microthrombosis, is the 
inhibition of endothelial NOS by oxyhemoglobin. In order to test this hypothesis, 
we measured the level of free hemoglobin in the plasma of mice subjected to 
experimental SAH, and compared it to that of healthy mice. Our results showed 
there is no increase in plasma hemoglobin at 3 hours and 24 hours after experi-
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mental SAH in mice. We found an increase in the plasma hemoglobin level of 
mice at 72 hours after experimental SAH, but the increase was not statistically 
significant. These findings practically rolled out direct inhibition of endothelial 
NOS by plasma hemoglobin as a mechanism involved in NO depletion that will 
subsequently result in early post hemorrhagic cerebral vasospasm after SAH.
The second part of this project was an intravital microscopy (IVM) study of cere­
bral microcirculation within 1-3 hours after experimental subarachnoid hemor­
rhage in mice. This time window is chosen because our ultimate aim is to study 
the cerebral microcirculation as close to the time of the hemorrhage as possible. 
In a study conducted in our laboratory in Munich, Friedrich et al. demonstrated 
the presence of microcirculatory changes up until three hours after subarachnoid 
hemorrhage (Friedrich, Muller et al. 2011).
Therefore, the two main objectives of the intravital microscopy study are:
1- To investigate the presence of microvasospasm and microthrombi within the 
cerebral microcirculation at the very early stages after SAH.
2- To investigate the role of perivascular hemoglobin in the e t io lo g y  o f N O  deple­
tion that is proposed to subsequently result in post- hemorrhagic vasospasm. 
This was achieved, indirectly, by studying the degree of correlation between the 
presence of microvasospasms and microthrombi within the blood vessels a n d  
the presence of perivascular blood in the respective vessels.
The findings of the study confirmed the presence of ischemic changes in form of 
microvasospasms and microthrombosis affecting about half of the blood vessel
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segments investigated during the interval of 1-3 hours after experimental SAH. 
We also found a very strong correlation between the distribution of these is­
chemic changes and the presence of perivascular blood; which suggests an im­
portant role for perivascular hemoglobin, present in the perivascular hematoma, 
in causing depletion of NO from the perivascular wall, which, subsequently, 
leads to post- hemorrhagic cerebral ischemia.
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C H A P T E R  2
M A TER IA L & M ETH O D S
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2.1. Animals
Male C57B16 mice (body weight of 20 to 26 g) were used for the current project. 
All animals were obtained from Harlan UK (Shaw’s Farm, Bichester, England), 
and cared for at all stages in accordance with the principals of European Com­
munities Council directive (86/609/EEC). All procedures and experiments in this 
project were approved by the research ethics committee of the Royal College of 
Surgeons in Ireland.
2.2. Anesthesia and monitoring
The animal had free access to food and water prior to surgery. General anes­
thesia was induced by inhalation of 5% isoflurane for 60 seconds followed by 
intraperitoneal injection of a combination of midazolam (5 mg/kg body weight; 
Roche Products Limited, Welwyn Garden City, United Kingdom), fentanyl (0.05 
mg/kg; Antigen pharmaceuticals, Co. Tipperary, Ireland), and medetomidin (0.5 
mg/kg; CP-Pharma Handelsges. MbH, Burgdorf. Germany). For procedures that 
require more than an hour, an additional intraperitoneal injection of a quarter of 
the induction dose was given to maintain anesthesia. After anesthesia was suc­
cessfully induced, the mice were orotracheally intubated and mechanically venti­
lated as previously described (Thai and Plesnila 2007). Briefly, the mice were 
placed on a 45° angled table, and intubated under direct vision using surgical 
microscopes. The endotracheal tube used for intubation was fashioned from a 
commercially available intravenous catheter by shortening the catheter tube to
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about 22 mm and its plastic connector to 4 mm. A small hole is also drilled at the 
tail end of the plastic connector in order to fit the sample tubing which will be 
connected to the microcapnometer (See fig. 1). The mice were then mechanical­
ly ventilated by connecting the orotracheal tube, through a Y connector, to a me­
chanical ventilator (Minivent, Hugo Sachs, Hungstetten, Germany). A controlled 
mixture of 35-40% oxygen in room air was used for ventilation. End tidal PC02 
was continuously measured by a microcapnometer (C1240, Columbus instru­
ments, Columbus, USA) and maintained at 30 to 35 mmHg by adjusting the ven­
tilation. Body temperature was maintained at 37°C by a thermostatically regulat­
ed feed-back controlled heating pad (FHC, Bowdoinham, USA). After completion 
of the planned experiment and animals were planned for further longer term ex­
periments, anesthesia was terminated by intraperitoneal injection of a combina­
tion of atipamezol (2.5 mg/kg; CP-Pharma Handelsges. MbH, Burgdorf. Germa­
ny), nalaxone (1,2mg/kg; Antigen pharmaceuticals, Co. Tipperary, Ireland) and 
flumazenil (0.5 mg/kg; Roche Products Limited, Welwyn Garden City, United 
Kingdom). Immediately after termination of anesthesia, the endotracheal tube 
was removed and animals were kept in an incubator at 33°C.
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Fig.i. The endotracheal tube. Note the metal tube that connects the endotracheal tube 
to the microcapnometer to measure ETPC02.
2.3. Surgical Induction of subarachnoid hemorrhage
SAH was induced in mice using the circle of Willis endovascular perforation 
model that was first described in rats (Bederson, Germano et al. 1995) and mice 
(Kamii, Kato et al. 1999; McGirt, Parra et al. 2002; Gao, Wang et al. 2006) and 
further characterized by Feiler and colleagues (Feiler, Friedrich et al. 2010). For 
description purposes, the procedure is explained in its consequential steps, by 
describing first the insertion of the intracranial pressure monitoring device, fol­
lowed by description of the vascular procedure leading to subarachnoid hemor­
rhage.
2.4. Intracranial pressure monitoring
After the animals were anaesthetized and the ventilation established, a small 
skin incision was made over the right temporoparietal area of the skull. The tem­
poralis muscle was then incised and detached from its upper attachment and 
displaced interiorly exposing the underlying bone. A small craniotomy was 
drilled at the junction between the upper and lateral surfaces of the skull and a 5 
mm intracranial pressure monitoring probe (Samba Preclin, Samba sensors, 
Vastra Frolunda, Sweden) was inserted into the epidural space for measuring of 
the intracranial pressure. Semi liquid bone cement was then applied over the 
craniotomy in order to firmly seal the craniotomy and, at the same time, fix the 
ICP probe to the skull. The probe was then connected to an intracranial pressure 
measurement device (Samba Preclin, Samba sensors, Vastra Frolunda, Sweden) 
for continuous monitoring of intracranial pressure.
2.5. Induction of subarachnoid hemorrhage
After placing the intracranial monitor, the animals were then placed in prone po­
sition and a midline neck incision was made to expose the left carotid artery and 
its two terminal branches. A thin prolene suture (Ethicon, San Lorenzo, Puerto 
Rico) was passed through the external carotid artery into the internal carotid ar­
tery and advanced intracranially. Successful induction of SAH was marked by a 
sudden and sharp rise in intracranial pressure. As the ICP start to rise, the mon­
ofilament was gently withdrawn through the external carotid artery and the latter 
tightly ligated.
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2.6. Measurement of free plasma hemoglobin
Free plasma hemoglobin was measured in 4 different groups of animals: the 
control group, healthy animals, (n = 5), 3 hours after SAH (n = 5), 24 hours after 
SAH (n= 6) and 72 hours following SAH (n = 6).
The spectrophotometric scanning method of Blakney and Dinwoodie (Kahn, 
Watkins et al. 1981) was used for determination of plasma hemoglobin.
2.7. Collection of plasma samples
At the desired time point animals were anaesthetized as described previously. 
With animals in supine position, a coronal incision was made just below the tho­
racic cage. The peritoneum was opened and the diaphragm clearly identified. A 
small incision was made across the right part of the diaphragm and gently ex­
tended onto its left side, opening the thoracic cavity from its inferior part. Care 
was taken to avoid excessive bleeding which could potentially lower the total 
blood volume. The heart was gently positioned so that the right ventricle is clear­
ly seen as the most anterior part of the heart. Using a 23 G needle attached to a 
1 ml syringe, about 450-600 nl of blood was very gently aspirated from the right 
ventricle. In order to avoid in vitro hemolysis at this stage, the ventricle was gen­
tly cannulated to avoid excessive tissue trauma, and the withdrawal of blood 
was done gently to avoid any turbulence during the blood flow into the syringe.
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The needle was then removed from the syringe, and the blood was gently trans­
ferred from the syringe into an Eppendorf tube. Both the syringe and the 
Eppendorf tube were pre-coated with heparin in order to avoid clotting of the 
blood sample, which can also cause in vitro hemolysis of the RBCs. The plasma 
was separated by centrifuging the blood in the Eppendorf tube, at a speed of 
1000 cycles/min for 10 minutes initially, then at a speed of 1600 cycles/min for 
20 minutes.
2.8. Procedure and calculation
About 50-100 |il of plasma was withdrawn from the supernatant solution, and di­
luted to 1000 pi using distilled water. Another solution of 1000 pi of distilled wa­
ter was prepared to serve as control in order to set the absorbance to zero each 
time the absorbance of the plasma solution was measured. Each of the two so­
lutions was placed in a separate chamber in the spectrophotometer. The ab­
sorbance of the plasma solution was measured three times at each of the wave 
lengths of 562, 578 and 598 nm. The mean values of these measurements were 
used to calculate the concentration of hemoglobin from the following equation: 
155 x A578-81 x A562-69 x A598 (Kahn, Watkins et al. 1981). The figures of 
155, 81, and 69 are the calibration factors for oxyhemoglobin, methemoglobin 
and bilirubin respectively, and the (A) stands for the mean absorbance values at 
the corresponding wave length (Kahn, Watkins et al. 1981). The result of this 
calculation was then multiplied by the factor by which the initial plasma volume
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was diluted to 1000 \x\. This final result represents the concentration of hemo­
globin in the plasma sample in mg/dl.
2.9. Intravital microscopy
Intravital microscopy was conducted using the model established in our labora­
tory in Munich (Kataoka, Kim et al. 2004; Schwarzmaier, Kim et al. 2010; 
Friedrich, Muller et al. 2011). After anesthesia and ventilation were established, 
animals were placed in a stereotactic frame (Stoelting Wood Dale, Illinois. 
U.S.A). A rectangular 15x15 mm cranial window was made over the left parie­
tal cortex. The Dura mater was left intact to preserve the anatomy of the sub­
arachnoid space. The window extends in the coronal plane from the attachment 
of the temporalis muscle to a point just lateral to the sagittal suture. In the sagit­
tal plane, the window extends from just behind the coronal suture to a point just 
in front of the occipital suture. A glass cover was placed over the window and 
firmly fixed to the skull bone surrounding the window using bone cement. The 
purpose of the glass cover was to prevent brain herniation which will otherwise 
take place secondary to brain edema that occurs early after subarachnoid hem­
orrhage.
After the cranial window was done, with the mouse still in the same position, the 
intracranial pressure monitor was inserted as prescribed previously.
The mouse was then placed in supine position, and a femoral catheter was in­
serted in the left femoral artery. Subsequently, subarachnoid hemorrhage was . 
induced as prescribed above.
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In sham operated animals, the same procedures were performed without induc­
ing subarachnoid hemorrhage, i.e. the monofilament was advanced into the in­
ternal carotid artery intracranially, but withdrawn before causing any change in 
base line ICP.
Once all the surgical procedures were completed, animals were transferred onto 
a computer controlled microscope stage for analysis of cerebral vasculature. 
Continuous monitoring of all physiological parameters (body temperature, 
ETPC02, MABP) was maintained throughout the duration of intravital microsco­
py, and arterial blood gas was measured at the end of the experiment.
Visualization of cerebral vasculature was achieved by intra-arterial injection of 
0.15 ml of fluorescein isothiocyanate-labeled dextran (FITC-dextran; molecular 
weight 150,000; Sigma-Aldrich, Wicklow. Ireland). The vascular tree of the 
ipsilateral middle cerebral artery, from arteriolar (10-80 pm) to capillary level (< 
10 |im), was studied by obtaining repeated short videos along vessel segments 
and subsequently analyzing the video images post-hoc.
2.10. Statistical analysis
Statistical analysis was done using SigmaStat 11. Plasma hemoglobin results 
were analyzed using one way analysis of variance (ANOVA). Data on the corre­
lation between microthrombosis and microvasospasm with perivascular blood 
were analyzed using Mann-Whitney Rank Sum test. Statistical significance was
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assumed at P <0.05. Data were presented as mean+/- SEM if not otherwise in­
dicated.
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C H A P T E R  3
R E S U L T S
Our data showed that plasma hemoglobin levels at 3 and 24 hours after experi­
mental subarachnoid hemorrhage are similar to the levels of plasma hemoglobin 
in control animals. At 72 hours after SAH, the levels are higher in SAH animals 
than control animals, but the difference is not statistically significant (Fig. 2).
3.1. Plasma hemoglobin levels
Con 3hrs 24hrs 72hrs
Time
Fig.2. Plasma hemoglobin levels 3, 24, and 72 hours after SAH compared to control. 
Data presented as mean+/-SEM. Values are: control: 3.9 +/- 0.6, 3 hrs: 4.2+/- 0.4, 24 
hrs: 3.5+/- 0.3, 72 hrs: 5.5+/- 0.4.
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3.2. Intravital Microscopy
3.2.1. Physiology:
Subarachnoid hemorrhage in mice produced a sharp and immediate rise irt in­
tracranial pressure (ICP) to 91 +/- 29 mmHg (mean +/- STD). The mean arterial 
blood pressure (MABP) was lower in the mice with subarachnoid hemorrhage 
compared to sham operated mice, but still remained within the physiological 
threshold of cerebral autoregulation for the vast majority of the duration of intra­
vital imaging (table 1). End tidal PC02 values remained within close range in 
both SAH and sham groups throughout the experiments, and this resulted in ar­
terial PC02 which is within normal physiological range in both groups (tables 2& 
3).
Table (1): Mean arterial blood pressure (MABP) values (mmHg) in sham and SAH 
mice (Mean +/- SEM) during IVM. Time (min) calculated from the start of IVM.
Time
into
IVM ~>
15 min 30 min 45 min 60 min 75 min 90 min 105
min
120
min
Sham 78 +/- 79 +/- 80 +/- 77 +/- 79 +/- 7 76. +/- 82 +/- 79 +/-
5.7 8.2 6.7 7.5 8.6 7.9 10.6
S A H 68 +/- 69 +/- 63 +/- 64 +/- 71 +/- 57 +/- 60 +/- 54+/-
5.4 3.9 4.3 2.5 7.1 2.4 2.7 2.7
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Table (2): End tidal PC02 values (mmHg) in sham and SAH mice (Mean +/- SEM) dur­
ing IVM. Time (min) calculated from the start of IVM.
Time
into
IVM ->
15 min 30 min 45 min 60 min 75 min 90 min 105
min
120
min
Sham 26 +/- 27 +/- 28+/- 27 +/- 27 26 +/- 26 +/- 26 +/-
0.4 0.7 0.6 0.5 +/- 0.7 0.7 0.9 0.8
S A H 26 +/-1 26 +/- 27 +/- 27 +/-1 27 +/- 26 +/- 26 +/- 26 +/-
0.9 0.7 0.9 0.8 0.9 0.8
Table (3): Arterial PC02 (mmHg) in sham and SAH mice (Mean +/- SEM).
Arterial PC02 
"Sham 39+/-2.7
. SAH 41 +/-1.8
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We were able to demonstrate the fact that the blood spreads from the source of 
bleeding at the circle of Willis at the base of the skull to the upper surface of cer­
ebral cortex. Blood is seen as a dark layer encasing the left middle cerebral ar­
tery as it curls from the skull base to the upper cortical surface, and continues to 
spread along the branches of the middle cerebral artery in the subarachnoid 
space (Fig. 2). 75% of all vessel segments investigated showed a similar pat­
tern. No blood was seen along the middle cerebral artery or any of its branches 
in the sham operated mice (Fig. 3).
3.2.2. Distribution of blood
Fig- 2: Left middle cerebral artery and its two main branches after subarachnoid hemor­
rhage. Note: the blood is seen as the dark layer coating the MCA and its branches (red 
arrows).
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Fig. 3: Left middle cerebral artery and its two main branches after sham surgery. Note: 
there is no blood surrounding the MCA or any of its branches
3.2.3. Vasospasm
In the time window of 1-3 hours after subarachnoid hemorrhage, numerous vas­
oconstrictions were observed in various vessel segments. In total, 96 areas of 
vasoconstrictions were observed in 123 vessel segments. The vasoconstriction 
showed a very characteristic pattern, in the form of repeated areas of vasocon­
striction interchanging with areas of normal vessel caliber in between (Fig. 4,5,
6 and 11). Analysis of the severity of vasoconstriction, i.e. the degree to which 
the vascular diameter is diminished, showed 38.6% of all the vasospasms re­
duced the constricted vessel diameter to 80-90% of the normal diameter, 32% 
reduced the vascular diameter to 70-80% of its norm, 20.4% diminished the vas-
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cular caliber to 60-70%, and 8% of the vasospasms causes reduction of the 
vascular caliber to 50-60% of normal caliber (Fig. 7).
In order to investigate the involvement of perivascular blood in the causation of 
vasospasm we analyzed vasospasms in the context of the presence or absence 
of perivascular blood. The vast majority of vasospasms occurred in the presence 
of perivascular blood; 93% of all vasospasm are associated with blood in the 
perivascular space compared to only 7% of vasospasm occurring in the absence 
of perivascular blood (Fig. 8).
Fig. 4: Multiple vasospasms affecting an arteriole. Note the vasospasms (straight ar­
rows) affect segments and spare the intervening segments. Presence of perivascular 
blood is also noted (twisted arrow).
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Fig. 5: Multiple vasospasms: The pattern of vasospasm affecting segments and sparing 
the adjacent segments (yellow arrows). Note perivascular blood along the arteriole (Red 
arrows) affected by the spasms. Also note perivascular blood following the arteriole 
deep into the brain tissue.
Fig. 6: Micovasospasm in an arteriole. Vasospasm affects a short segment (long arrow) 
of the arterioles, and sparing the adjacent segment. Note the presence of perivascular 
blood (short arrow).
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Fig. 7: The degree of vasospasm. Figures represent the percentage of narrowing at the 
constricted segments; i.e. the percentages of the vascular diameter at the constricted 
segment from the original vessel diameter. (n= 96 VS in 73 vessels).
100
VS with PVBD VS without PVBD.
Fig. 8: Vasospasm (VS) in the presence of perivascular blood (PVBD) Vs vasospasm in 
the absence of PVBD. *P -  0.002 VS with PVBD (n= 96 VS in 73 vessels).
Microthrombi were identified by accumulation of FITC-dextran in blood vessels, 
and were associated with cessation of blood flow in the respective blood vessel 
seen during imaging. They were seen as a lump of accumulated FITC-dextran 
(Fig. 9), or in the form of accumulated FITC dextran extending through the entire 
length of the microarterioles or capillaries (Fig. 10,11 &12). A total of 34 
microthrombi were detected during the period of imaging. Similar to vasospasm, 
a close correlation between the distribution of microthrombi and the presence of 
perivascular blood is noted. 79% of all micro thrombi were observed in vessels 
coated with perivascular blood, compared to 21% of micro thrombi detected in 
the absence of perivascular blood (Fig. 13).
3.2.4. Microthrombi
Fig. 9: Microthrombus in an arteriole: seen as focal accumulation of FITC dextran (red 
arrow).
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Fig. 10: Microthrombi: extensive microthrombi occupying the entire length of the capil­
laries (red arrows).
Fig. 11: Microthrombi completely occlude the entire arteriole/s (short arrows). 
Microvasospasms (long arrows (Right)) affecting two segments of the arteriole with 
normal segments in between. Note the presence of perivascular blood as dark layer ad­
jacent to the arterioles (twisted arrows).
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Fig. 12: Microthrombi (arrows) occluding the arteriole and extends into its branches.
100
MT with PVBD MT without PVBD
Fig. 13: Microthrombi (MT) in the presence of perivascular blood (PVBD) versus 
microthrombi in the absence of PVBD. * P= 0.026 Vs MT with PVBD. (n= 34 MT in 73 
vessels).
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In order to determine the vessel category mostly affected by vasospasm and 
thrombosis, we analyzed the distribution of vasospasm and thrombosis among 
different vessel sizes. Our results showed that the vast majority of vasospasms 
and thrombi occurred in small arterioles and capillaries (Fig. 14). About 39% of 
all vasospasms were detected in vessels with 10-20 |im caliber, 28% of vaso­
spasms occurred in vessels with 20-30 |im caliber and 10% in blood vessel size 
of 30-40 urn. Only 2% of vasospasms were seen in larger vessels (>60 |im in 
diameter). With regards to thrombi, 59% of them were seen in vessels <10 |im in 
diameter and 37% affected vessels with 10-20 |jm in diameter. There were no 
thrombi seen any vessel larger than 30 |jm in diameter (Fig. 15).
3.2.5. Distribution of vasospasm and thrombosis according to vessel size
< 10 1 0 - 2 0 .2 0 - 3 0  3 0 -4 0  4 0 -5 0  5 0 -6 0  6 0 -7 0  7 0 -8 0  8 0 -9 0  9 0 -1 0 0
Vessel size (jim)
Fig. 14: Distribution of vasospasm among different vessel sizes. Vasospasm was pre­
dominantly detected in small arterioles and capillaries (diameter 10-30 |jm). (n= 96 VS 
in 73 vessels)
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Fig. 15: Distribution of microthrombi (MT) among different vessel sizes. Thrombosis 
predominantly affects capillaries and small arterioles. (n= 34 MT in 73 vessels).
3.2.6. Perivascular blood and vasospasm and thrombosis
We also analyzed the association between the presence of perivascular blood 
and the development of vascular changes in the form of microvasospasms 
and/or microthrombi collectively. In this study only 34% of vessels segments 
which showed perivascular blood did not develop vasospasm or microthrombi. 
This means that though perivascular blood is not always associated with vascu­
lar changes, in two third of the cases its presence did coincide with the devel­
opment of these vascular changes.
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Since 75% of all segment investigated showed perivascular blood, we calculated 
the total percentage of segments with either microvasospasm or 
microthrombosis from all the segments investigated. We found 56% of all seg­
ments investigated showed either microvasospasm or microthrombosis.
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C h a p t e r  4
D IS C U S S IO N
There is little doubt that hemoglobin is released from slow hemolysis of the 
RBCs within the subarachnoid clot and is directly or indirectly responsible for the 
development of cerebral vasospasm after subarachnoid hemorrhage. NO de­
pletion, which results from the scavenging effect of hemoglobin on NO (Goretski 
and Hollocher 1988; Ignarro 1990) and decreased production of NO through in­
hibition of NO synthesis (Nozaki, Moskowitz et al. 1993; Pluta, Thompson et al. 
1996; Jung, Oldfield et al. 2007), is widely accepted as a potential mechanism 
by which hemoglobin causes post hemorrhagic cerebral vasospasm (Pluta ; 
Pluta, Dejam et al. 2005; Jung, Oldfield et al. 2007; Sehba and Bederson 2011). 
Identification of the levels of free hemoglobin within different body fluid com­
partments after subarachnoid hemorrhage augments the understanding of the 
mechanisms by which free hemoglobin can cause NO depletion, and subse­
quently lead to post hemorrhagic cerebral vasospasm. So far, hemoglobin and 
its metabolites have been detected in the subarachnoid clot (Kajikawa H Fau - 
Ohta, Ohta T Fau - Yoshikawa et al.), the perivascular fluid (Kajikawa H Fau - 
Ohta, Ohta T Fau - Yoshikawa et al.) and the cerebrospinal fluid (Kajikawa H 
Fau - Ohta, Ohta T Fau - Yoshikawa et al. ; Barrows, Hunter et al. 1955; Suzuki, 
Muramatsu et al. 2003) in patients with aneurismal subarachnoid hemorrhage. 
Oxyhemoglobin has been found in the cerebrospinal fluid (CSF) as early as 2 
hours after aneurismal subarachnoid hemorrhage, and continued to be detected 
for up to two weeks (Barrows, Hunter et al. 1955; Macdonald and Weir 1991). 
However, no correlation has been found between CSF oxyhemoglobin levels
4.1. Plasma hemoglobin
and the severity of vasospasm (Kajikawa H Fau - Ohta, Ohta T Fau - Yoshikawa 
et al.). The lack of correlation between CSF oxyhemoglobin concentration and 
the severity of cerebral vasospasm can be explained by the fact that lumbar 
CSF concentrations of oxyhemoglobin do not accurately reflect concentrations in 
the perivascular space immediately contiguous to spastic vessels. The results of 
the clinical studies measuring the perivascular hemoglobin concentrations after 
subarachnoid hemorrhage have been largely inconclusive (Kajikawa H Fau - 
Ohta, Ohta T Fau - Yoshikawa et al.). Theoretically, the only other fluid in direct 
contact with the vascular wall, and could carry excess hemoglobin that could 
have an impact on the vascular physiology, is the plasma. Therefore, in this 
study, we measured the level of free hemoglobin in the plasma at three different 
time points during the first 72 hours after subarachnoid hemorrhage. Our data 
showed the presence of normal plasma free hemoglobin concentrations for up to 
72 hour after subarachnoid hemorrhage. This is an important observation which 
can lead to valuable clues in the implication of free hemoglobin in the etiology of 
acute post- hemorrhagic cerebral vasospasm. The presence of normal intravas- 
cular hemoglobin concentration after subarachnoid hemorrhage, which shown in 
our data, excludes direct inhibition of endothelial NOS by plasma hemoglobin as 
a possible mechanism involved in NO depletion. This conclusion prompted us to 
investigate the role of perivascular hemoglobin that is present in the perivascular 
hematoma as a major player in NO depletion from the vessel wall. Our findings 
and conclusions in this regard are part of the findings of the intravital microscopy 
study, which is described below.
The main purpose of conducting the intravital microscopy study was to closely 
examine the cerebral microcirculation for the presence of microvascular ischem­
ic changes in the immediate aftermath of experimental subarachnoid hemor­
rhage. Our findings confirmed the presence of pearl-and -string like vasocon- 
strictions affecting almost half of all the vessel segments investigated within the 
interval of 1-3 hours after SAH. At these constrictions, the vascular diameter was 
reduced to an extent which could lead to reduced blood flow. Another significant 
observation from this study is the presence of microthrombi within 
microarterioles and capillaries at such an early time point after SAH. The pres­
ence of microthrombi as early as 10 minutes after subarachnoid hemorrhage 
has been described in histological sections after experimental subarachnoid 
hemorrhage in mice (Sehba, Mostafa et al. 2005). In this study, we were able to 
demonstrate microthrombosis along with microvasospasm under physiological 
conditions in living mice, thus avoiding all the shortcomings of other none in vivo 
models.
The main strength of this study is that two well established methods were used 
to conduct the study. For induction of experimental subarachnoid hemorrhage 
we used the endovascular perforation model, which has the advantage of re­
sembling human aneurismal subarachnoid hemorrhage in having an injured ar­
tery leading to hemorrhage under direct arterial blood pressure. For imaging of 
cerebral vasculature after subarachnoid hemorrhage, the intravital fluorescence
microscopy technique was used. The combined use of these two techniques, as
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4.2. Intravital microscopy
described, has enabled us to study cerebral microcirculation under controlled 
physiological conditions. The physiological parameters that could directly affect 
cerebral vasculature were continuously monitored and kept within their normal 
range throughout each experiment. The mean arterial blood pressure (MAP) 
was constantly at levels within the cerebral autoregulation threshold in both ex­
perimental groups, and its values were within similar range in both the sham and 
SAH groups (Table 1). End tidal PC02 levels were controlled by adjusting the 
ventilation during the experiments and served as an index for arterial PCOs lev­
els. Thus, the levels of arterial PC02 measured at the end of each experiment 
were within the normal physiological range in both experimental groups (Tables 
2 & 3). Therefore, we are confident that all the necessary precautions were tak­
en to avoid any influence of the current experimental methods on the pathophys­
iological processes under investigation.
4.3. Microvasospasm and microthrombosis
The findings of this study demonstrate the presence of ischemic changes in the 
form of vasoconstriction and thrombosis at the microcirculatory level as early as 
1 hour after experimental subarachnoid hemorrhage. These findings support the 
hypothesis suggested by Bederson (Bederson, Germano et al. 1995; Bederson, 
Levy et al. 1998) and others (Schubert, Seiz et al. 2011) that cerebral ischemia 
after subarachnoid hemorrhage is caused by vasoconstriction at the level of 
cerebral microcirculation. There have been few recent clinical studies reaching
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the same conclusion i.e. vasoconstriction, at the level of microcirculation, plays 
an important role in the causation of post hemorrhagic cerebral ischemia 
(Schubert, Seiz et al. 2009; Schubert, Seiz et al. 2011). Moreover, Uhl et al, ac­
tually, demonstrated microvasospasms affecting cerebral microcirculation in pa­
tients with aneurismal subarachnoid hemorrhage (Uhl, Lehmberg et al. 2003). 
However, none of these clinical studies were done within the very first few hours 
following the hemorrhage, and hence, little is known about the pathological 
events that occur immediately after aneurismal subarachnoid hemorrhage in 
humans. Revisiting the statistics of the outcome of aneurismal SAH shows that 
16% of all patients who suffers from SAH die before they reach medical care, 
which practically implies they die within the first few hours following SAH 
(Pobereskin 2001; Macpherson, Lewsey et al. 2011). This fact shows the prog­
nostic importance of the pathological events within this short period of time after 
SAH and the need to understand these events in order to develop appropriate 
therapeutic measures that will help improve the outcome of these patients. Our 
data have shown that within an hour after experimental subarachnoid hemor­
rhage, large areas of the middle cerebral artery microcirculation are affected by 
microvasospasm and microthrombosis severe enough to cause cerebral ische­
mia. This conclusion is drawn from two main observations noted from our data. 
First, a closer look at the percentage of reduction of the vascular diameter at the 
sites of vasospasms shows that 28.4% of all vasospasms resulted in at least 
30% reduction of the vascular diameter, and a further 32% of all vasospasms 
has led to a reduction of the vascular diameter by 20-30% (Fig. 7).The effects of
such reductions in vascular diameter on blood flow within any particular blood 
vessel can be drawn from Hagen- Poiseuille law, which indicates that vascular 
blood flow decreases by r4 (r is the diameter). Hence, reduction of the vascular 
diameter by, for example, 30% will reduce vascular blood flow by 81% indicating 
marked reduction of flow in blood vessels affected by such degree of vaso­
spasms. The effect of reduction of vascular diameter on blood flow is expected 
to be exacerbated by microthrombi, the presence of which indicates occlusion of 
the vascular lumen and cession of blood flow within the affected segments irre­
spective of the vascular diameter. Overall, 56% of all the vessel segments inves­
tigated in this study were affected by either vasospasm or thrombosis (or both). 
Second, both vasospasm and thrombosis predominantly affected the small arte­
rioles and capillaries (Fig.14 & 15), and because these are mostly end arteries, 
their occlusion is likely to result in cerebral ischemia. Whether the same vascular 
changes happen during the same period of time in patients with aneurismal 
subarachnoid hemorrhage and to the same extent and severity remains to be 
seen.
Microthrombosis has also been reported in a number of clinical studies in pa­
tients with aneurismal subarachnoid hemorrhage. In a very interesting autopsy 
study published in 2006 on 29 patients who died from aneurismal subarachnoid 
hemorrhage, Stein et al. demonstrated that microthrombi are present in abun­
dance in these patients, and their presence is strongly correlated with clinical 
and pathological signs of ischemia (Stein, Browne et al. 2006). These autopsy 
findings were further supported by radiological studies in living patients with an-
eurismal SAH showing widespread radiological changes across both cerebral 
hemispheres consistent with microembolic occlusion of cerebral microcirculation 
(Kivisaari, Salonen et al. 2001; Romano, Forteza et al. 2002; Rabinstein, 
Weigand et al. 2005). The strongest evidence was reported by Romano et al., 
who demonstrated microembolic signals on transcranial Doppler ultrasonogra­
phy studies in 16 out of 23 patients (70%) with aneurismal subarachnoid hemor­
rhage (Romano, Forteza et al. 2002). These autopsy and radiological evidence 
of widespread microthrombosis in cerebral microcirculation in patients with an­
eurismal subarachnoid hemorrhage are supported by several hematological 
studies which showed activation of coagulation system as well as fibrinolytic 
system early during the course of aneurismal subarachnoid hemorrhage (Fujii, 
Takeuchi et al. 1995; Peltonen, Juvela et al. 1997; Nina, Schisano et al. 2001; 
Morga, Czepko et al. 2007). Morga et al. measured the plasma thrombin- 
antithrombin-3 complex (TAT) (a marker for coagulation system), and D- dim­
mers (markers for fibrinolytic system) in 72 patients with aneurismal SAH at the 
time of admission, and 7 days after aneurysm surgery, and compared them with 
to those of 84 patients without SAH. They concluded that SAH causes activation 
of both coagulation and fibrinolytic system and such activation is associated with 
poor clinical status at the time of admission and poor outcome later (Morga, 
Czepko et al. 2007). Similar findings were reported by Nina et al., who showed 
evidence of early activation of coagulation and fibrinolytic system in a series of 
76 patients with SAH, and found a strong correlation between the plasma 
thrombin-antithrombin-3 (TAT) and D dimmers levels and the clinical outcome of
these patients (Nina, Schisano et al. 2001). Few other.studies have confirmed 
this strong correlation between the scale of derangement of hemostatic cas­
cades and the clinical outcome of patients with aneurismal subarachnoid hemor­
rhage (llveskero S Fau - Juvela,. Juvela S Fau - Siironen et al. ; Kusanagi H Fau 
- Teramoto, Teramoto A Fau - Shimura et al. ; Itoyama, Fujioka et al. 1994; Fujii, 
Takeuchi et al. 1995). Such is the extent of this correlation that some authors 
regard markers of coagulation state in the early periods after aneurismal sub­
arachnoid hemorrhage as independent factors in determining the patients’ out­
come after aneurismal subarachnoid hemorrhage (Fujita K Fau - Tamaki and 
Tamaki; Juvela S Fau - Siironen and Siironen ; Nina, Schisano et al. 2001; 
Morga, Czepko et al. 2007). (Sehba, Mostafa et al. 2005). Studies that compare 
the levels of these markers in the CSF and jugular venous blood to that of sys­
temic venous blood have shown that these markers are much higher in the CSF 
and jugular venous blood compared to systemic levels, indicating that the hy­
percoagulability state after subarachnoid hemorrhage originates from the cere­
bral circulation (Denton, Robertson et al. 1971; Juvela, Hillbom et al. 1991). The 
mechanisms responsible for activation of coagulation system after aneurismal 
subarachnoid hemorrhage are not clear. It’s speculated to be caused by release 
of tissue thromboplastins from damaged brain tissue into the circulation 
(Yamamoto, Clower et al. 1991; Fujii, Takeuchi et al. 1995). Platelets function in 
humans during the early stages after aneurismal subarachnoid hemorrhage is 
poorly understood. Most of the data in literature on platelets function in patients 
with aneurismal subarachnoid hemorrhage came from Juvela and colleagues in
Helsinki, Finland. They have shown, in numerous studies, increased platelets 
aggregation and thromboxane release during the course of delayed cerebral 
vasospasm, suggesting a causative role for platelets aggregation and throm­
boxane in the development of delayed cerebral vasospasm and delayed ischem­
ic neurological deficit in patients with aneurismal subarachnoid hemorrhage 
(Juvela 1990; Juvela, Kaste et al. 1990; Juvela, Kaste et al. 1990; Juvela,
Ohman et al. 1991). There are similar reports of platelets activation and aggre­
gation at later stages after experimental subarachnoid hemorrhage in animals 
(Denton, Robertson et al. 1971; Ohkuma, Suzuki et al. 1990; Ohkuma, Ogane et 
al. 1993; Pisapia, Xu et al. 2011). However, Platelets aggregates in the lumen of 
small parenchymal vessels causing perfusion deficit have been demonstrated as 
early as 10 minutes after experimental subarachnoid hemorrhage in two studies 
by Sehba et al. (Sehba, Mostafa et al. 2005; Friedrich, Flores et al. 2010). Inter­
estingly, they reported the presence of constricted vessel segments in otherwise 
normal vessels located next to these platelets aggregates (Friedrich, Flores et 
al. 2010). The mechanisms behind platelets activation and aggregation following 
subarachnoid hemorrhage are not fully understood. Endothelial injury, leading to 
loss of normal endothelial inhibitory effect on platelet aggregation, is regarded 
as a potential mechanism responsible for platelets aggregation in parenchymal 
vessels after SAH (Ohkuma, Suzuki et al. 1990; Ohkuma, Ogane et al. 1993; 
Akopov, Sercombe et al. 1996). Another important mechanism thought to play a 
key role in platelets activation and aggregation after subarachnoid hemorrhage 
is NO depletion (Sehba, Schwartz et al. 2000; Friedrich, Flores et al. 2010). Un­
der normal physiological conditions, NO inhibits platelets adhesion and aggrega­
tion. Therefore, depletion of NO from the vessel wall, which is known to occur 
after SAH, will likely remove its inhibitory effects on platelets adhesion and ag­
gregation, leading to platelets aggregation within the vascular lumen (Friedrich, 
Flores etal. 2010).
Two previous experimental studies (Friedrich, Flores et al. 2010; Friedrich, Mul­
ler et al. 2011) have shown that, microthrombi and microvasospasms are pre­
dominantly found adjacent to each other in the same vessel. This observation 
suggests either a common pathology is mediating both microvasospasm and 
microthrombosis, or they both play a part in the formation of one another. It’s al­
so possible that both scenarios occur at the same time. NO depletion is likely to 
be the common pathology that has the potential to result in the formation of both. 
Oxyhemoglobin induced NO depletion from the vascular wall is now seen as the 
most likely mediator of post hemorrhagic microvasospasms (Jung Cs Fau - 
luliano, luliano Ba Fau - Harvey-White et al. ; Pluta ; Nozaki, Moskowitz et al. 
1993; Pluta, Dejam et al. 2005; Jung, Oldfield et al. 2007; Sehba and Bederson 
2011). It’s also believed that lack of NO increases platelets activation and ag­
gregation (Yamamoto, Clower et al. 1991; Friedrich, Flores et al. 2010), and al­
ters the antithrombotic properties of the endothelial cells (Yamamoto, Clower et 
al. 1991; Ohkuma, Ogane et al. 1993); both actions can lead to the formation of 
microthrombi in the vascular lumen. Reduction of the vessel diameter at the site 
of microvasospasm leads to reduced blood flow through the vessel lumen, and if 
that is severe enough, it can cause stasis of blood proximal to the constriction.
As we know, stasis is a strong predisposing factor for the formation of thrombi 
within any given blood vessel. Once a microthrombus is formed it can either re­
main at the same size, or increase in size and occupy a longer segment of the 
arteriole through the phenomena of thrombus propagation. This explains the two 
types of microthrombi we encountered in this study (Fig. 9-12). The observation 
that microthrombi were detected mainly at the proximal end of the constricted 
segments perfectly support this hypothesis. On the other hand, microthrombi 
can also cause or potentiate the formation of microvasospasm (Okada,
Copeland et al. 1994; Park, Yamaguchi et al. 2004). Platelets activation and ag­
gregation which occur at the site of microthrombi lead to release of 
thromboxanes (Juvela 1990; Juvela, Kaste et al. 1990; Juvela, Kaste et al. 1990; 
Juvela, Ohman et al. 1991) and other potent vasoconstrictors such as ADP, ser­
otonin and PDGF (Okada, Copeland et al. 1994; Park, Yamaguchi et al. 2004) 
from platelets into the surrounding, and these are carried distal to the thrombus, 
where the vasoconstrictions occur. The most likely scenario is that 
oxyhemoglobin induced NO depletion causes both microvasospasm and vaso­
constriction, and both then act in a synergistic manner to potentiate each other. 
This hypothesis is supported by our findings and the findings of others, which 
showed that there is a strong correlation between the distribution of both 
microvasospasms and microthrombi (Honma, Clower et al. 1989; Yamamoto, 
Clower et al. 1991; Stein, Browne et al. 2006) and the presence of perivascular 
or subarachnoid blood, and also by the fact that the status of coagulation after 
aneurismal subarachnoid hemorrhage correlates well with the amount of sub­
arachnoid blood as shown in many studies (Fujii, Takeuchi et al. 1995; Morga, 
Czepko et al. 2007).
4.4. Perivascular blood and the etiology microvasospasm and microthrombosis
The second aim of the intra-vital microscopy study was to investigate the role of 
perivascular hemoglobin in the etiology of NO depletion that will eventually re­
sults in microvasospasm and microthrombosis, by estimating the degree of cor­
relation between the distribution of mirovasospasms and microthrombi and the 
presence of perivascular blood. Our findings showed a very strong correlation 
between the presence of microvasospasm and microthrombi in the blood ves­
sels and the presence of perivascular blood adjacent to the vessel wall. The 
contents of perivascular blood were examined by.Pluta and colleagues in a 
model of subarachnoid hemorrhage where they place clotted arterial blood over 
the right middle cerebral artery in monkeys. They found the levels of 
oxyhemoglobin and deoxyhemoglobin in the perivascular fluid increase during 
the development of delayed cerebral vasospasm (Pluta, Afshar et al. 1998). De­
spite the limitations of the model used in comparison with the endovascular per­
foration model, and their focus on delayed cerebral vasospasm, the results of 
their study provide a strong link between elevated level of perivascular hemo­
globin concentration and cerebral vasospasm. Our study is the first to describe a 
closer correlation between acute microcirculatory ischemic changes and the 
presence of perivascular blood in direct contact with the adventitia of blood ves­
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sels. By establishing this strong link between perivascular blood and the devel­
opment of microvasospasm and microthrombi, and taking into account the pres­
ence of normal plasma hemoglobin levels at the time of these observations, we 
add to the evidence supporting the theory that, blood and blood products, pre­
sent in the perivascular space and coating cerebral arterioles, play a causative 
role in the etiology of microvasospasm, and microthrombi, leading to occlusion 
of cerebral microcirculation, which is ultimately responsible for post hemorrhagic 
cerebral ischemia in patients with SAH. These findings are consistent with those 
of Fisher and Kistler et al. who have shown, in two consecutive studies, that the 
volume and distribution of blood within the subarachnoid space determine the 
distribution and the severity of vasospasm in patients with SAH (Fisher, Kistler 
et al. 1980; Kistler, Crowell et al. 1983; Findlay, Macdonald et al. 1991). They 
concluded from their studies that, by quantifying the subarachnoid blood volume 
on the CT scan of these patients we can accurately predict whether or not they 
are going to develop vasospasm and, accordingly, ensure appropriate prophy­
lactic measures against cerebral vasospasm. In their famous autopsy study; 
Stein et al. found a strong correlation between the presence of microthrombi and 
the overlying subarachnoid blood (Stein, Browne et al. 2006). The extent of acti­
vation of the coagulation and fibrinolytic cascade, which is seen early after aneu- 
rismal subarachnoid hemorrhage is also shown to be proportionate to the 
amount of subarachnoid blood identified on the CT scans of these patients (Fujii, 
Takeuchi et al. 1995; Morga, Czepko et al. 2007). There is further evidence in 
the literature which can explain the mechanisms by which perivascular hemo­
globin can cause NO depletion. Intense NOS activity has been detected in the 
nerve endings in the adventitia of cerebral vessels of monkeys (Pluta, Thomp­
son et al. 1996), rats and humans (Nozaki, Moskowitz et al. 1993), adding an­
other important source of NO for the vessel wall. These adventitial NOS con­
taining nerves mediates neurogenic cerebral vasodilatation (Toda and Okamura 
1990; Toda and Okamura 1991; Nozaki, Moskowitz et al. 1993; Pluta, Thomp­
son et al. 1996). It has been shown that these nerve endings are damaged in 
vessels exposed to blood or oxyhemoglobin (Toda and Okamura 1990). Fur­
thermore, more recent reports confirmed the disappearance of NOS activity from 
the adventitial nerve endings in cerebral vessels in spasm, while at the same 
time immunoreactivity of endothelial NOS was preserved in these vessels 
(Pluta, Thompson et al. 1996). This will clearly suggest the loss of vasodilatory 
input from the adventitia in response to the presence of blood in the perivascular 
space, is a key element in the etiology of post hemorrhagic cerebral vasospasm. 
These findings, together with the findings of Fisher and Kistler et al. of a rather 
localized nature of post hemorrhagic cerebral vasospasm, mostly in areas with 
subarachnoid blood, are inconsistent with an exclusively intravascular origin for 
the etiology for vasospasm, as intravascular pathologies are more likely to be 
more generalized. The results of our two studies together, i.e. the strong corre­
lation between the presence of perivascular blood and the development of 
microvasospasm and microthrombosis, and the observation of normal plasma 
hemoglobin level at the time of vasospasm and microthrombosis, are also in­
consistent with an intravascular pathology. Hence, NO depletion after subarach­
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noid hemorrhage is unlikely to be due inhibition of endothelial NO synthase by 
increased intravascular hemoglobin. Perivascular hemoglobin, scavenging the 
available NO and, at the same time, inhibiting NOS in the adventitial nerve end­
ings leading to depletion of NO from the vessel wall, seems to be, in our opinion, 
the more likely mechanism of NO depletion, which is thought to be responsible 
for acute cerebral vasospasm after subarachnoid hemorrhage. The potential 
therapeutic implication of the extra-vascular pathogenesis of post hemorrhagic 
cerebral vasospasm is that any therapeutic agent has to be able to reach the 
perivascular space to have the desired effects.
4.5. Oxyhemoglobin: the principle agent responsible for vasospasm
The hemoglobin metabolites which have been linked with a possible role in cer­
ebral vasospasm are oxyhemoglobin, bilirubin and methemoglobin. 
Methemoglobin is a product of autoxidation of oxyhemoglobin, while bilirubin is 
the result of enzymatic breakdown of oxyhemoglobin. Several studies have 
shown bilirubin does not possess vasospasmatic action on cerebral arteries in 
vitro (Macdonald and Weir 1991). Although elevated levels of bilirubin have 
been detected in CSF of patients with SAH, these levels were not associated 
with vasospasm (Suzuki, Muramatsu et al. 2003). Most in vivo studies on 
methemoglobin concluded that it has no vasoconstriction effect on cerebral ar­
teries (Macdonald, Weir et al. 1991). Oxyhemoglobin, on the other hand, 
showed definite spasmodic action when applied to cerebral arteries (Macdonald,
69
Weir et al. 1991), and its levels were elevated in the perivascular fluid of cere­
bral arteries affected by vasospasm (Pluta, Afshar et al. 1998). Therefore, of all 
the hemoglobins, oxyhemoglobin is regarded as the principal pathogen respon­
sible for alteration of vascular physiology after subarachnoid hemorrhage 
(Asano ; Kajikawa H Fau - Ohta, Ohta T Fau - Yoshikawa et al.; Macdonald, 
Weiretal. 1991; Pluta, Oldfield etal. 1997). The mechanisms by which 
oxyhemoglobin causes vasospasm, are not fully understood. Possibilities in­
clude: scavenging (Goretski and Hollocher 1988; Ignarro 1990; Sehba, Schwartz 
et al. 2000) and decrease production (Martin, Villani et al. 1985; Sehba,
Schwartz et al. 2000) of NO, the release of free radicals (Misra and Fridovich 
1972; Gao, Ding etal. 2009; Munakata, Ohkuma etal. 2011), the initiation and 
propagation of lipid peroxidation causing increased production of vasoactive 
eicosanoids and endothelins (endothelin 1) from arterial wall (Toda 1990), induc­
tion of structural damage to the arterial wall (Ostrowski, Colohan et al. 2006), 
stimulation of neuronal apoptosis (Cahill, Calvert et al. 2006; Cheng, Wei et al.
2009), and evoking of an inflammatory reaction through increased expression of 
cell adhesion molecules which leads to rolling, adhesion and extravasation of 
leukocytes (Momin, Schwab et al. 2009). These actions are complex and closely 
connected and ultimately result in imbalance of the autoregulation of the vascu­
lar tone in favor of vasoconstriction.
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The mechanisms of action of oxyhemoglobin, which are proposed to explain its 
role in the etiology of vasospasm, have been the basis of clinical trials looking 
for effective therapies that can reduce the incidence of post hemorrhagic cere­
bral vasospasm and improve the outcome of patients with aneurismal subarach­
noid hemorrhage. The most recent example is the endothelial receptor antago­
nist, clazosentan, clinical trials (Vajkoczy, Meyer et al. 2005; Macdonald, Kassell 
et al. 2008; Macdonald, Higashida et al. 2011). These trials are based on the 
observations that oxyhemoglobin causes increased production of endothelin -1, 
which is a potent vasoconstrictor protein (Kasuya, Weir et al. 1993), and the 
findings of elevated levels of endothelin-1 in the cerebrospinal fluid of human 
and animals with post hemorrhagic cerebral vasospasm (Pluta Rm Fau - Boock, 
Boock Rj Fau - Afshar et al.; Seifert, Loffler et al. 1995; Zimmermann and Sei­
fert 1998). The latest report on these trials is phase 3 of randomized double­
blind, placebo- controlled trial of the endothelin-1 receptor antagonist, 
clazosentan (Macdonald, Higashida et al. 2011). This is a large multi-center clin­
ical trial involving 1157 patients with aneurismal subarachnoid hemorrhage, in 
27 countries, over a period of 18 months. Despite significant reduction of the in­
cidence of moderate to severe vasospasm in patients treated with clazosntan in 
this trial, there was no significant improvement in morbidity or mortality or func­
tional outcome. This efficacy against angiographic vasospasm, which did not 
translate into improved clinical outcome, have prompted the investigators in this 
clinical trial to conclude that, factors other than delayed cerebral vasospasm
4.6. Clinical trials against vasospasm
contribute to ischemic brain injury and poor functional outcome after aneurismal 
subarachnoid hemorrhage. These factors, in their opinion, are likely to be micro- 
circulatory dysfunction and early brain injury. The findings of our current study 
point towards a similar conclusion; i.e. microcirculatory failure, due to vaso­
spasm and thrombosis across cerebral microcirculation in the acute stages of 
subarachnoid hemorrhage, is a major contributor to ischemic brain injury and 
poor functional outcome after aneurismal subarachnoid hemorrhage.
Other clinical trials based on other mechanisms of action of oxyhemoglobin have 
also been unsuccessful in improving patients’ outcome. Tirilazad, a free radical 
scavenger and an inhibitor of lipid peroxidation, was used in five randomized, 
double-blind and placebo-controlled clinical trials to assess its effects on unfa­
vorable outcome, symptomatic vasospasm and cerebral infarction after aneu- 
rismal subarachnoid hemorrhage (Kassell, Haley et al. 1996; Haley, Kassell et 
al. 1997; Lanzino and Kassell 1999; Lanzino, Kassell et al. 1999). The results 
from these trials showed that although tiriiazad did decrease the incidence of 
angiographic vasospasm, it did not improve the clinical outcome of patients with 
aneurismal subarachnoid hemorrhage (Jang, llodigwe et al. 2009). Statins, 
which have an anti-inflammatory effects and upregulate endothelial NO syn­
thase, have also been used in clinical trials to test its efficacy against angio­
graphic vasospasm and poor functional outcome after aneurismal subarachnoid 
hemorrhage (Lynch, Wang et al. 2005; Tseng, Czosnyka et al. 2005; Tseng, 
Hutchinson et al. 2007; Chou, Smith et al. 2008; Vergouwen, de Haan et al.
2010). The results from these trials were conflicting, but overall it did not have
beneficial effects on angiographic vasospasm or the patients’ outcome 
(Vergouwen, de Haan et al. 2010).
4.7. Nitric oxide donors: promising therapeutic potential
The hypothesis that hemoglobin induced NO depletion is responsible for post 
hemorrhagic cerebral vasospasm has gain support from the success of thera­
pies based on repletion of NO in tackling vasospasm and improving outcome of 
patients with aneurismal SAH. Administration of nitric oxide, through various 
routes, successfully ameliorates the development of vasospasm both in clinical 
and experimental settings (Thomas Je Fau - Rosenwasser and Rosenwasser; 
Egemen, Turker et al. 1993; Thomas, Nemirovsky et al. 1997; Pluta, Dejam et 
al. 2005). Afshar et al. showed, in an experimental subarachnoid hemorrhage in 
monkeys, that intracarotid infusion of NO solution increases cerebral blood flow, 
decreases vascular resistance and reverse angiographic vasospasm without 
producing profound systemic hypotension (Afshar, Pluta et al. 1995). More re­
cently, Momin et al. implanted an NO donor molecule (diethylenetriamine 
(DETA)/NO incorporated into ethylene/vinyl acetate (EVAc) polymers) into the 
cisterna magna of mice that are genetically susceptible to post hemorrhagic 
vasospasm (haptoglobin 2-2 mice), to evaluate the role of continuous delivery of 
NO on vasospasm. In this study, they shown that controlled release of NO into 
the subarachnoid space prevents vasospasm and, more importantly, minimizes 
neurological deficit in these mice (Momin, Schwab et al. 2009). These encourag­
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ing results of NO donors from experimental studies were translated into clinical 
research, which is so far showing promising results.
Various preliminary clinical studies on small numbers of patients using 
intrathecal or intraventricular sodium nitroprusside, an NO donor molecule, for 
the treatment of severe post hemorrhagic vasospasm refractory to conventional 
therapy have, indeed, shown good to excellent outcome (Thomas and McGinnis 
2002; Pathak, Mathuriya et al. 2003; Agrawal, Patir et al. 2009). Raabe et al. 
studied the effects of intraventricular administration of sodium nitroprusside on 
cerebral hemodynamics in 13 patients suffering from severe refractory vaso­
spasm following aneurismal subarachnoid hemorrhage (Raabe, Zimmermann et 
al. 2002). In 6 of the 13 patients enrolled in the study, intraventricular sodium 
nitroprusside produced a marked improvement in cerebral circulation time (CCT) 
and brain tissue oxygenation (Pbro2), reflecting an improved cerebral blood flow 
(Raabe, Zimmermann et al. 2002). In another study, Thomas et al. studied the 
effects of intrathecal sodium nitroprusside (ITSN) on treatment and prevention of 
angiographic vasospasm and ischemic neurological deficit in 21 patients with 
poor grade aneurismal subarachnoid hemorrhage (Thomas, Rosenwasser et al. 
1999). In 12 patients in this study, ITSN was administered after the onset of se­
vere angiographic vasospasm and resulted in reversal of the vasospasm, de­
creased cerebral circulation time and improved clinical outcome. In 9 other pa­
tients ITSN was administered prophylactically and was successful in preventing 
vasospasm and ischemic neurological deficits. All the patients in this study have 
favorable outcome (Thomas, Rosenwasser et al. 1999). In a similar study
Agrwal et al. used intraventricular sodium nitroprusside to treat 10 patients with 
poor grade subarachnoid hemorrhage (Hunt and Hess grade 2 and higher) and 
compared the outcome to 10 patients with similar grades who served as controls 
(Agrawal, Patir et al. 2009). All 10 patients who received the IVSN showed im­
proved cerebral blood flow on transcranial Doppler studies, and the overall clini­
cal outcome was good or excellent in 7 of those 10 patients (Agrawal, Patir et al. 
2009). Although a substantial vasodilation of large-caliber cerebral vessels in 
response to SNP was demonstrated in these studies, its beneficial effects are 
more likely to be due to its vasodilatory effects on small blood vessels at the lev­
el of cerebral microcirculation. This is reflected by improvement of collateral cir­
culation, shortening of circulation time, sometimes without dramatic change in 
the diameter of the large-caliber vessels, which have also been noted after ad­
ministration of SNP in these studies (Thomas, Rosenwasser et al. 1999; Raabe, 
Zimmermann et al. 2002; Agrawal, Patir et al. 2009). The predominant effect of 
SNP on small blood vessel which is concluded from these studies is consistent 
with the nature of NO molecule as the smallest biologically active molecule in 
nature, making it capable of penetrating tissues directly (Thomas, Rosenwasser 
et al. 1999). Relatively thinner walls of smaller vessels render them more sus­
ceptible to the effects of NO donors administered to the adventitia (in this case 
intraventricular or intrathecal) causing them to respond faster, therefore improv­
ing cerebral blood flow (Thomas Je Fau - Rosenwasser and Rosenwasser ; 
Raabe, Zimmermann et al. 2002; Thomas and McGinnis 2002). In addition, the 
NO molecule will also be able to penetrate the brain tissue and the subarach­
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noid clot and the perivascular blood that coats the blood vessels in order to 
reach the vascular wall and exert its desired effects. This is clinically very rele­
vant, because local administration via intrathecal or intraventricular route is not 
only effective in reducing the risk of ischemic brain damage, but also minimizes 
the hypotensive and other undesired side effects of NO donors which are more 
likely to occur with systemic administration. It’s also noted that continuous or re­
peated administration of SNP is more efficient and produce better outcome than 
administration of a single dose (Thomas, Rosenwasser et al. 1999). In some 
cases vasospasm redeveloped a few hours following single dose administration 
(Thomas, Rosenwasser et al. 1999). This has been explained by the fact that 
oxyhemoglobin rapidly absorb the NO that is delivered with single dose admin­
istration, whereas intermittent or continuous administration will provide constant 
supply of NO that overwhelms oxyhemoglobin scavenging capacity (Thomas, 
Rosenwasser et al. 1999). Overall, the findings from nitroprusside studies and 
those from experimental studies on NO donors for the treatment of vasospasm 
points towards a key role for microcirculatory dysfunction in the etiology of is­
chemic brain damage and poor functional outcome after aneurismal subarach­
noid hemorrhage. The results of our current studies are in line with these find­
ings.
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There are some limitations to our current study. Although the study showed evi­
dence of microcirculatory occlusion as early as one hour after the hemorrhage, 
it’s still unclear how soon after subarachnoid hemorrhage these changes start to 
occur. As the period immediately after subarachnoid hemorrhage has the high­
est mortality rate (Pobereskin 2001; Macpherson, Lewsey et al. 2011), it will be 
intriguing to study cerebral circulation immediately after subarachnoid hemor­
rhage i.e. as close to the moment of the hemorrhage as possible. If it’s proven 
that these changes occur right after the hemorrhage, as we expect, then that will 
confirm the role of microcirculatory failure in the etiology of post hemorrhagic 
cerebral ischemia throughout all the stages after subarachnoid hemorrhage. 
Theoretically, that means that early microthrombosis and microvasospasm rep­
resent a target for novel therapeutics techniques that will lower the overall mor­
tality and morbidity from subarachnoid hemorrhage. More importantly, it will pro­
vide hope to lower the pre-hospital mortality (the highest mortality group) if any 
therapy against vasospasm and thrombosis can be delivered to patients before 
they reach medical care. On the other hand, if raised ICP is the reason behind 
this high pre-hospital mortality, it will be practically impossible to address and 
the mortality at this stage will remain high.
The other limitation of the study is that the technique only allows imaging of ves­
sels on the surface of the brain. It’s not clear from the study if these changes oc­
cur in parenchymal blood vessels. Although we are not able to show it yet, we 
expect these changes to affect the parenchymal vessels as well. Although it’s
4.8. Weaknesses of the study
not formally and statistically proven in this study, we could notice from some im­
ages that perivascular blood follows blood vessels as they leave the surface of 
the brain heading deep into the parenchyma (Fig. 5). As perivascular blood is 
shown to strongly associate with microthrombosis and microvasospasm on the 
surface, it's expected that the same occur at the parenchymal level. Most of the 
studies that reported microthrombosis in patients with aneurismal subarachnoid 
hemorrhage have shown these microthrombi mainly occur in the deep parts of 
the brain (Kivisaari, Salonen et al. 2001; Romano, Forteza et al. 2002; 
Rabinstein, Weigand et al. 2005; Stein, Browne et al. 2006). We are not aware 
of any clinical study showing vasoconstriction in deep parenchymal blood ves­
sels, but most experimental studies so far describing microthrombosis have 
shown that microthrombi are accompanied by microvasospasm in most cases 
(Friedrich, Flores et al. 2010).
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This study shows as early as one hour after subarachnoid hemorrhage there are 
changes in cerebral microcirculation in the form of microvasospasms and 
microthrombosis that are severe enough and extensive enough to cause cere­
bral ischemia. The presence of these changes in cerebral blood vessels was 
shown to strongly correlate with the presence of perivascular blood, suggesting 
a causative role for blood and blood products that are in direct contact with the 
adventitia of blood vessels in the development of microvasospasm and 
microthrombosis after subarachnoid hemorrhage. It’s known from the literature 
that oxyhemoglobin is the most important blood product involved in the etiology 
of vasospasm. The presence of normal plasma hemoglobin after subarachnoid 
hemorrhage, along with the strong correlation between microvasospasm and 
microthrombosis and the presence of perivascular blood, as shown in this study, 
support the widely accepted theory that perivascular oxyhemoglobin is respon­
sible for the development of post hemorrhagic vasospasm through depletion of 
nitric oxide from the vessel wall. These findings suggest that microcirculatory 
failure plays a significant role in the etiology of the early brain injury that occurs 
after aneurismal subarachnoid hemorrhage and accounts for the high mortality 
and morbidity associated with the disease. NO depletion from the vessel wall, 
which is induced by perivascular oxyhemoglobin, is the most likely mechanism 
responsible for acute microcirculatory failure and the early brain injury that fol­
lows and results in high morbidity and mortality after subarachnoid hemorrhage.
5.1. Conclusions
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As expected with any experimental study, the findings from this study bring 
some important questions. Based on the results of this study we can make the 
following suggestions for future research:
1- Examination of the microcirculation deep in the brain parenchyma after sub­
arachnoid hemorrhage
It will be very interesting to examine the parenchymal microcirculation to see if 
microvasospasm occurs in parenchymal vessel as well, and to see if perivascu­
lar blood follows the cerebral vessels deep in the brain tissue. This can be 
achieved by using the intravital microscopy model as described here, with the 
only modification being using two photon imaging modality, instead of the cam­
era we used in this study.
2- Investigation of the therapeutic potentials of NO donors and hemoglobin 
scavengers
We conclude by supporting the role of adventitial oxyhemoglobin induced NO 
depletion in the etiology of microvasospasm and microthrombosis which is re­
sponsible for cerebral ischemia and early brain injury after subarachnoid hemor­
rhage. Therefore, in theory, in order to prevent or reverse vasospasm and 
thrombosis, NO has to be constantly delivered to the vessel wall, or 
oxyhemoglobin completely removed from perivascular space.
5.2. Recommendation for future research
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NO donors that provide NO to the vessel wall have already been used in prelim­
inary clinical studies, and the results from these are so far encouraging. Larger 
multicentre clinical trials are needed to test the efficacy of NO donors in revers­
ing vasospasm and improving clinical outcome in patients with aneurismal sub­
arachnoid hemorrhage.
Hemoglobin scavengers
Removal of oxyhemoglobin from perivascular space can, in theory, be achieved 
either surgically or chemically. However, it’s practically impossible to surgical 
remove all the perivascular blood in cases of aneurismal subarachnoid hemor­
rhage because blood spread along blood vessels across both hemispheres, and 
the obvious difficulty of achieving this at microcirculatory level. The other option 
is to chemically remove oxyhemoglobin from the perivascular space by deliver­
ing hemoglobin scavengers such as haptoglobin into the perivascular space. 
Haptoglobin is a naturally occurring plasma protein predominantly synthesized 
in the liver as an acute response protein (Zhao, Song et al. 2009). Its main phys­
iological function is to bind and neutralized cell free hemoglobin (Boretti Fs Fau - 
Buehler, Buehler Pw Fau - D'Agnillo et a l.; Asleh, Guetta et al. 2005; Levy,
Asleh et al. 2010). It has been shown that haptoglobin reverses the vascular 
complications of cell free hemoglobin seen in conditions associated with raised 
intravascular hemoglobin such as sickle cell disease and cerebral malaria 
(Boretti Fs Fau - Buehler, Buehler Pw Fau - D'Agnillo et al.). Haptoglobin is also
NO donors
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produced by oligodendroglial cells in the brain where it serve to protect neurons 
against the cytotoxic effects of hemoglobin through its powerful scavenging ef­
fect on cell free hemoglobin (Zhao, Song et al. 2009). Zhao et al. have shown 
that pharmacological or genetic induction of the synthesis of haptoglobin in the 
brain reduces the extent of brain damage after intracerebral hemorrhage in ani­
mals (Zhao, Song et al. 2009; Zhao, Song et al. 2011 ).
Therefore, with the proven efficacy of haptoglobin against complications caused 
by cell free hemoglobin in other diseases, further research can be conducted to 
test the efficacy of haptoglobin in reducing vasospasm and thrombosis in cases 
of subarachnoid hemorrhage. In theory, there are two ways by which 
haptoglobin can be delivered onto the adventitial site of blood vessels, where 
the oxyhemoglobin is anatomically located: genetically or pharmacological in­
duced overproduction of haptoglobin in the brain tissue, or surgical administra­
tion into the CSF circulation through the ventricle or subarachnoid cisterns. 
However both techniques are likely to have some limitations to overcome in or­
der to produce any desired effects. Surgical administration will have the limita­
tion caused by the fact that CSF circulation is disturbed in subarachnoid hemor­
rhage, which might hinder the delivery of CSF haptoglobin to areas of the brain 
affected by vasospasm. Pharmacological induction of overproduction of 
haptoglobin might be technically more feasible, but is expected to require time 
before it produces significant increases in haptdglobin levels in the brain tissue 
that are capable of producing the desired effect. Nonetheless, these foreseen 
limitations should not prohibit research into the therapeutic potential of
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haptoglobin and other hemoglobin scavenger in aneurismal subarachnoid hem­
orrhage, at least at experimental level.
84
A P P E N D IC E S
Appendix 1
Ethical approval
Royal C o lle g e  o f  Surgeons in  Ireland
T h e  R esearch  E th ic s  C o m m itte e
12} S l  S tephens G re en , D u b lin  2. Ire lan d.
T e l:  +353 1 4022373 Fax; +353 1 4022449 E m a il: ie c a d n u n @ rc s U e
D r . D a v id  S m ith . A c t in g  C h a ir  
M b . S te ph an ie  O ’C o n n o r , C o n v e n o r
R o y a l  C o l l e g e  o f  S u r g e o n s  in  I r e l a n d
CclLitsit? !\ioc)a no n ^u in lcu  in ¿ ir in n K C S I
2 1  O c t o b e r ,  2 0 1 0
M r  K h a l i d  A b u  b a k e r .
D e p a r t m e n t  o f  N e u r o d e g e n e r a t j o n ,  
R o y a l  C o l l e g e  o f  S u r g e o n s  in  I r e l a n d ,  
1 2 3  S t .  S t e p h e n ' s  G r e e n ,
D u b l i n  2 .
I r e l a n d
E t h i c s  R e f e r e n c e  N o : R E C 5 8 6
P r o j e c t  T i t l e : M e c h a n i s m s  o f  b r a i n  d a m a g e  f o l l o w i n g  s u b a r a c h n o i d  
h a e m o r r h a g e
R e s e a r c h e r s  N a m e : M r  K h a l i d  A b u b a k e r
O t h e r  I n d i v i d u a l s  I n v o l v e d : P r o f e s s o r  N i k o l a u s  P l e s n i l a ,  R C S I  
P r o f e s s o r  C i a r a n  B o l g e r ,  R C S I
D e a r  M r  K h a l i d  A b u b a k e r ,
T h a n k  y o u  f o r  y o u r  w e l l  w r i t t e n  R e s e a r c h  E t h i c s  C o m m i t t e e  ( R E C )  a p p l i c a t i o n .
W e  a r e  p l e a s e d  t o  a d v i s e  t h a t  e t h i c a l  a p p r o v a l  h a s  b e e n  g r a n t e d  b y  t h e  c o m m j t t e e  f o r  t h i s  s t u d y .
T h i s  l e t t e r  p r o v i d e s  a p p r o v a l  f o r  d a t a  c o l l e c t i o n  f o r  t h e  t i m e  r e q u e s t e d  in  y o u r  a p p l i c a t i o n  a n d  f o r  a n  
a d d i t i o n a l  6  m o n t h s .  T h i s  i s  t o  a l l o w  f o r  a n y  u n e x p e c t e d  d e l a y s  in  p r o c e e d i n g  w i t h  d a t a  c o l l e c t i o n .  
T h e r e f o r e  t h i s  r e s e a r c h  e t h i c s  a p p r o v a l  w i l l  e x p i r e  o n  2 1 “  A p r i l ,  2 0 1 3 ,
W h e r e  d a t a  c o l l e c t i o n  I s  n e c e s s a r y  b e y o n d  t h i s  p o i n t ,  a p p r o v a l  f o r  a n  e x t e n s i o n  m u s t  b e  s o u g h t  f r o m  t h e  
R e s e a r c h  E t h i c s  C o m m i t t e e .
T h i s  e t h i c a l  a p p r o v a l  i s  g i v e n  o n  t h e  u n d e r s t a n d i n g  t h a t ;
•  A l l  p e r s o n n e l  l i s t e d  in  t h e  a p p r o v e d  a p p l i c a t i o n  h a v e  r e a d ,  u n d e r s t a n d  a n d  a r e  t h o r o u g h l y  f a m i l i a r  
w i t h  a ) l  a s p e c t s  o f  t h e  s t u d y .
■  A n y  p e r s o n  u s i n g  a n  a n i m a l  f o r  s c i e n t i f i c  p u r p o s e s  i s  i n  p o s s e s s i o n  o f  a  v a l i d  l i c e n s e  f r o m  t h e  
D e p a r t m e n t  o f  H e a l t h  a n d  C h i l d r e n  f o r  t h e  p r o j e c t .
•  A  m a x i m u m  n u m b e r  o f  6 0 0  a n i m a l s  ( m i c e )  w i l l  b e  u s e d  f o r  t h i s  s t u d y .
•  A n y  s i g n i f i c a n t  c h a n g e  w h i c h  o c c u r s  i n  c o n n e c t i o n  w i t h  t h i s  s t u d y  a n d / o r  w h i c h  m a y  a l t e r  i t s  e t h i c a l  
c o n s i d e r a t i o n ,  m u s t  b e  r e p o r t e d  i m m e d i a t e l y  to the REC, and an ethical a m e n d m e n t  s u b m i t t e d  
w h e r e  a p p r o p r i a t e .
W e  w i s h  y o u  a l l  t h e  b e s t  w i t h  y o u r  r e s e a r c h .  
Y o u r s  s i n c e r e l y ,
P P  M s .  S t e p h a n i e  O ' C o n n o r  ( C o n v e n o r )  
D r  D a v i d  S m i t h  ( A c t i n g  C h a i r )
1810-2010
86
Appendix 2 Animal license
§
An Roinn Sláinte 
agus Leanai
D0*KTM£NT OF HEALTH AND C H ID *»*
Ref. B 100/4341
02/09/2010
Dr Nikolaus Plesnila 
Royal College o f  Surgeons Ireland 
123 St Stephens Green 
Dublin 2
CRUELTY TO ANIMALS ACT, 1876
As amended by European Communities (Amendment of Cruelty to Aninvils Act 1876) 
Regulation» 2-002 and 2005
A Chira
I am to forward herewith a licence which has been granted to you by the Minister for 
Health and Children to enable you  to perform experiments on live animals under the 
Cruelty to Animals A c l  1876 as amended. Certificates A & B have been noted.
Your licence now expires on the 27th August 2015 and i f  you require any further 
licences it will be necessary for you to re-apply before that time. Please allow  
sufficient time for the application to be processed. Any new experiment which has not 
been detailed in your application for this licence will require re-application.
M ise le  meas
, ^ f j  J r¡
Ciarán H egajft /  
Environm ental Health Unit
Cuartear Sfiiit* ¡s fflh  c^isnf < n ù te iw t
A r Boina Slétot» mgu* L + * n jl/O » !» r\rr+n\ of 4 ChMrvn
HaVítons HOUW DtfWn ? F0n/T»l «01) 635 « 0 0  M M p N M M a  ntoetiM *.h.gov.ie
H«*cín Bate Atha C l*tfi 2 Facs/Fa* (C1) 63!i 4301 Suwmrtv arfathMnWefc wwv* M k  «■
87
J3c
Q>
S'
' C '
< b
IIB
0
1
.20,CO
1 .  
£
\T3fli
c/>
^ 2
m
. 1
c;
H « .
0 
§ ■•a 
S
1
rn?
O
III
M X
■.S'.i
s-s■si*
t l ' H;aS "g « «•*
t r i ii , t 00,
J5 g,
m :
I T .00:1
'*: '-
;| l  ,111 •*? o o © •6«M »-:
SS :ssso o b i o
,E t.
I
f  W% -¿HI
1  I l i f t j j
. f e & S £  
^  -» iE i#  i f f c
•S; •:-j:J:e
l . i l l l l l i l ;
• --f. *3
'*5 ' -O:-: ?o-
■* $&» ¿5--!y::s:
& •
*d 
In 
th
at
 b
ef
ta
ft 
by
 
th
e 
sa
id
 
M
in
is
te
r

?tòke;;ìs;;^  « é.g.^aràiysis  ^inabilitato ^ spealc ori
under$tand;;à>m3;or death,. due io;jrnpàiredibloòd supply ¡n-ther brain/It can bo Indubed by óf
haemorrha^  leadingcause^
/inid.us i^^z j^iwuntnes;; Despite recent advancesjnUhe treati^ni of¿trol^lessth^
:•:■ receive cauiaf* tfea^nC : i ,£.■: ; tHèattnint I that.preyerits Jjalh Idamage;- ■ ^ eréfpre\fceré;ìs;Ìa nl tiigentfneeel ; in h 
:ciarif^ng stroke causes brahvda^ge; in s
‘Cerebral
mortality,sie T; hemorrhagic" stroke ? 
t99S) !^ Ote'pfc.tftef™^  >rMvére;.rauses' f«r^  HermrrKaglc^  sm>l^ is^ ^^ bàraic^ n^»d^ tie<ra
[A d e ta fle d  p ro to co l¿m u st à l8 o ;t » '8 u b m Ìt t ^ . lF % ;diagniosUc a n d  cif each/procedure"
^van^irand;Rihi<e||20dt %Despite facts'aad>^ r ^ j '^ <^p]^ys^l l^^r'similarlties;':SAH.!is by far less
f ^ q u e n U y ; ^  tHan-^;ischemtc^strak '^  ^ ' •^vei^^'im^riant iaspects ^ of : the:?
paUiophy Si oiogy i ofSlAHjareVn qt''¿weji :.pefin£i3: there i$jf\hamjpN^ 
s^^gies/^Cahnraful'^angVl^pOdy^
It is known.that cerebral 'blood;flow;{CBFlts few;houi^afe;SAHfan'd teLthetresiilting;
.cferebraijsch^^ impoi^ni:^^ .
, tHe. cerebral .'p^^slbn:prwsiure^CPPJ '^c^Bn'^normarfeiiowtftg !S>W;andriarge ^  
t$$h e 'm 3m :re3 !^ f6£^
: the, case h e ¿mi^ciicuiailon=' isiaffe^e^; WhafV mechanisms ? are ? responsi ble i for.
mjcrpcircL-^ tqiy feiiurejfoiiowin^ 
unknown' yet.
.Therpfpre:;thel8»m;;Of.;tHeicurrent;^seaitb;.proj^
^ S A H r in ^ ^
.- Aim 'i:': investigate 
“C^panVpyreflis/ai^^^
3li^aocj;|jh.;aftef SAH
Aim 3: Investigate,the cerebral hiicn^rcutatfon foilcrv6,ing 'experimental SAH by' jntravilal fiuoresoencB
microscopy oyer1ime:C3h^  Sh'ii-l 2 h ^ t^  ;24h; andi72h);:
A^j4:-llwest^«e::^l>^ft^^jp^'ral;;y«seisj-rea^;tpi; priy^ogical; sttmuit ^ Cp^adre^iine^^ 
following ^perimenta,l;;SAH!by'ifeyit2ifiupiiescence
Aim 5: Measure nitric oxide production in cerebral endothelial cells following experirrisntal SAH;by.intrayital 
fjuore^h^
Atm 6: Jwestigate the role of ■the.nitrjic oxide system: for SAH-indub^brair^
..o^ ema^ formatim^ neu ;:
Aim 7: Measure free haemoglobin in plasma following experimental: SAH over ttme:{1 min, .15 min,{30 min,1h; 
3h,6h, 24h, and 72h)
Aim;8: Investigate?how application of; free: haemoglobin scavengers modulate.microvasospasm and brain;,, 
injury following experimental SAH (before, 1 min. 30* mln,1h, 3h, and 6h)'
Aim 9; Investigate the blood plasma, brain tissuetÄ * terebra! vesseí pro^me fd^wingexpëiimemàl?SÀH: 
overtime íih,;3h,:6h, 12h; 18h,:24h,'46h. and.72h);
: Alm I nvestigate the rolë ôf inflaWirfiaiorÿ ceils ahcf inflammation ÎorSAH-inducedibraiti mjtiry;{neuronaî. 
■cèihdeaih, brain:oedermfbrmatiDn; neuronalifunctipn ; ^ before; ;l;rr¿n, 30 minali;-3h, and 6h)
Appendix 3
SAH Protocol
Department of Neurodegeneration, RCSI 
Dr. KhalidAbubaker, Ref(B 100/4299).
SAH protocol
Experiment:_____________  Date
Protocol: '________  REC No:
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Mouse No:_____________
Sex: Male Female
Strain: C57 BI6 TIE2GFP ThylCFP
Weight:___ g
Start:___ :___ h End:____:___ h
Anaesthesia: Isoflurane: concentration % duration sec
Triple combination (I.P) dose: Induction: ____ ml maintenance: _____ ml
Right temporal mini-craniotomy for ICP probe: Start Time:___ :___ h End Time:
___ :___ h
ICP monitoring: Start Time:___ :___ h value: SAH Time:___ :___ h value:
End___ :___ h Value
Carotid preparation: start time: ___ :___ h end time:___ :___ h
Right femoral artery catheterization: Start:___ :___ h End:___ :___ h ABG sam­
pling: Y/N
Cranial window:
IVM:
Brain extraction:
Specials:
Signature:
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Protocol for measurement of plasma hemoglobin 
Anesthesia: triple combination
Surgery: supine position, Coronal incision below the diaphragm. Gentle dissection 
while dissecting skin and opening the peritoneum to avoid bleeding and minimize tissue 
trauma.
Make a small incision on the right part of the diaphragm. Extend the incision gently on 
to the left side, care not to cause bleeding by damaging the inferior vena cava or the 
heart.
Isolate the heart and position it so the right ventricle is clearly seen.
Aspiration of blood: use appropriate needle size needle to avoid hemolysis, (not too big 
to cause trauma to the heart or too small to cause hemolysis while aspirating). Normally 
size 23G.
The syringe is coated with heparin by installing one drop of heparin into it and rinsing 
the whole length of it with this one drop and then aspirating to dryness ( So that no 
drops of heparin left over in the syringe).
Aspirate blood from the heart very gently: avoid turbulence at any stage. Special atten­
tion when withdrawing the needle from the heart, make sure there is no negative pres­
sure in the syringe because this will cause turbulence and hence hemolysis.
Aspirate 500 to 600|iL of blood in 1 ml syringe pre-coated with heparin as mentioned 
above.
Remove the needle and gently empty the blood into heparin coated Eppendorf tube.
Pre-coat the Eppendorf tube by filling it with heparin and then aspirate to dryness (so 
that no heparin drops are left behind).
Centrifugation:
1000 CPM for 10 min+ 1600 CPM for 20 min 
Aspirate 50-100 \iL of plasma into I000 pL tube 
Complete to volume to 1000 jjL by adding distilled water 
Spectrophotometry:
Get the absorbance at 562, 578 , 598 wavelengths.
Appendix 4
Protocol for measurement of plasma hemoglobin
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Multiply the result by the dilution factor
The result is plasma hemoglobin concentration in mg/dl.
Apply the results into this equation: 155XE578-81xE562-69XE598
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